Cancer in Maryland: 2015 Incidence and Mortality Report
This page left blank intentionally
Cancer in Maryland: 2015 Incidence and Mortality Report

Maryland Cancer Registry
Center for Cancer Prevention and Control (CCPC)
Cancer and Chronic Disease Bureau
Prevention and Health Promotion Administration
Maryland Department of Health

This report is supported with funds from the Maryland Department of Health, the Maryland Cigarette Restitution Fund Program, and the Centers for Disease Control and Prevention, National Program of Cancer Registries (Grant Number-5NU58DP006333).
Prepared by:

Maryland Cancer Registry (MCR) Staff

Afaq Ahmad, Epidemiologist; Jennifer Hayes, Senior Epidemiologist; Delores Rich, Program Coordinator; and Kimberly Stern, Program Manager.

Westat Inc. (MCR Quality Assurance/Database Management)

Carmela Groves, Quality Assurance Technical Specialist; Mary Mesnard, Quality Assurance Manager; and Wilhelmina Ross, Quality Assurance Technical Specialist.

Acknowledgements

This report would not be possible without the support and diligence of tumor registrars at Maryland reporting facilities whose hard work is greatly appreciated.

We would like to thank the following organizations and individuals for their tireless efforts and contributions towards this report:

- Cancer reporting facilities that provide cancer cases to the Maryland Cancer Registry: hospitals, laboratories, ambulatory care facilities, therapeutic radiological centers, physicians, nursing facilities, assisted living programs and general hospice care programs.

- Erica Smith, M.S., Epidemiology Team Lead, Center for Cancer Prevention and Control, Maryland Department of Health.

- Ken Lin Tai, M.D., M.P.H., Director, Center for Cancer Prevention and Control, Maryland Department of Health.

- MCR Quality Assurance and Database Management contractors at Westat, Inc.

- Maryland Vital Statistics Administration: Lee Hurt, M.D., Ph.D., Director, and Helen Espitallier, M.S., Data Production Manager.

- The registries of the states of Alabama, Arkansas, California, Colorado, Delaware, Florida, Georgia, Idaho, Louisiana, Massachusetts, Michigan, Montana, Nebraska, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Virginia, West Virginia, and the District of Columbia who provide cancer cases of Maryland residents diagnosed and/or treated in their facilities.

- The North American Association of Central Cancer Registries and the Centers for Disease Control and Prevention’s National Program of Cancer Registries.

Funding for the Maryland Cancer Registry is provided by the state of Maryland general funds, the Maryland Cigarette Restitution Fund, and the Centers for Disease Control and Prevention’s National Program of Cancer Registries.
TABLE OF CONTENTS

I. Data Highlights
   A. Incidence ....................................................................................................7
   B. Mortality ....................................................................................................7

II. Introduction
   A. Maryland Cancer Registry (MCR).............................................................8
   B. MCR Operations ........................................................................................8
   C. Organization of this Report........................................................................9

III. Data Collection and Management
   A. Reporting Facilities....................................................................................9
   B. Cancer Case Reporting and Definition ......................................................9
   C. Registry Certification..................................................................................12
   D. Quality Control/Quality Assurance (QC/QA) ...........................................12
   E. Data Confidentiality...................................................................................12

IV. Data Charts
   
   Maryland Cancer Incidence Cases by Selected Site, Race, and Gender ...13
   
   Table I 1: Cancer Sites and All Sites Combined for Maryland: Count,
   Age-Adjusted Incidence Rates, and 95% Confidence Interval
   by Gender and Race .......................................................................................15

   Table I 2: Cancer Sites and All Sites Combined for Maryland: Count,
   Age-Adjusted Incidence Rates, and 95% Confidence Interval
   by Gender and Race for Males ..............................................................17

   Table I 3: Cancer Sites and All Sites Combined for Maryland: Count,
   Age-Adjusted Incidence Rates, and 95% Confidence Interval
   by Gender and Race for Females ..............................................................19

   Maryland Cancer Mortality Cases by Selected Site, Race and Gender ....21

   Table M 1: Cancer Sites and All Sites Combined for Maryland: Count,
   Age-Adjusted Mortality Rates, and 95% Confidence Interval
   by Gender and Race .......................................................................................23

   Table M 2: Cancer Sites and All Sites Combined for Maryland: Count,
   Age-Adjusted Mortality Rates, and 95% Confidence Interval
   by Gender and Race for Males .......................................................................25
Table M3: Cancer Sites and All Sites Combined for Maryland: Count, Age-Adjusted Mortality Rates, and 95% Confidence Interval by Gender and Race for Females .......................................................... 27

V. 2015 Maryland Incidence and Mortality Selected Cancer Rates (Maryland and by County)

Maryland Incidence and Mortality Cancer Fact Sheet .......................................................... 31
Allegany County .................................................................................................................. 32
Anne Arundel County ...................................................................................................... 33
Baltimore City ................................................................................................................... 34
Baltimore County .............................................................................................................. 35
Calvert County .................................................................................................................. 36
Caroline County ............................................................................................................... 37
Carroll County .................................................................................................................. 38
Cecil County ....................................................................................................................... 39
Charles County .................................................................................................................. 40
Dorchester County ............................................................................................................. 41
Frederick County ............................................................................................................... 42
Garrett County ................................................................................................................... 43
Harford County .................................................................................................................. 44
Howard County .................................................................................................................. 45
Kent County ........................................................................................................................ 46
Montgomery County ......................................................................................................... 47
Prince George’s County ..................................................................................................... 48
Queen Anne’s County ....................................................................................................... 49
Somerset County ............................................................................................................... 50
St. Mary’s County ............................................................................................................. 51
Talbot County ..................................................................................................................... 52
Washington County ......................................................................................................... 53
Wicomico County .............................................................................................................. 54
Worcester County ............................................................................................................. 55

VI. Appendices
B. Glossary ......................................................................................................................... 63
I. DATA HIGHLIGHTS

Data presented in this report includes cancers reported for the year 2015 and are presented as age-adjusted rates and number of cancer cases and deaths by gender and race.

A. Incidence
   - A total of 31,001 new cases of invasive cancer were diagnosed among Maryland residents in 2015.

   - Most frequently diagnosed cancer by gender:
     - *Males:* Prostate cancer was the most frequently diagnosed cancer among Maryland men with a total of 4,063 new cases reported in 2015.
     - *Females:* Breast cancer was the most frequently diagnosed cancer among Maryland women with a total of 4,876 new cases reported in 2015.

B. Mortality
   - 10,568 Maryland residents died as a result of any type of cancer in 2015, making cancer the second leading cause of death in Maryland.

   - Cancer of the lung and bronchus was the most common cause of cancer deaths among Marylanders, with 2,579 cancer deaths in 2015. When observed separately by sex, lung and bronchus cancer was the leading cause of death among both men and women.

Data suppression rules for this report can be found at:
II. INTRODUCTION

According to the Maryland Cancer Registry (MCR), a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer is the second leading cause of death in the United States, exceeded only by heart disease. In the U.S., cancer accounts for nearly one out of every four deaths; in 2015, approximately 589,430 Americans died of cancer (more than 1,615 people a day), and in Maryland, 10,568 people died from cancer.

A. Maryland Cancer Registry (MCR)

The MCR collects all new cases of reportable cancers diagnosed and/or treated in Maryland and is the State of Maryland’s official source for cancer statistics.

History

In 1992, the Maryland General Assembly enacted Maryland Health-General Article §§ 18-203 and 18-204 which required hospitals, radiation therapy centers, and in- and out-of-state cancer diagnostic laboratories (that provide services to Maryland physicians) to electronically report all cancer cases diagnosed and/or treated in Maryland beginning July 1, 1993. In 1996, the laws were amended to require freestanding ambulatory care facilities, surgical centers, and physicians (whose non-hospitalized patients are not otherwise reported by either a hospital, radiation therapy center, surgical center or ambulatory care facility) to report cancer cases diagnosed and/or treated beginning with cases diagnosed January 1, 1999.

In 2001, the Maryland General Assembly enacted House Bill 636, requiring the reporting of benign brain and central nervous system tumors to the MCR effective October 2001.


Interstate data collection

On August 4, 2016, the MCR signed the National Interstate Data Exchange Agreement through the NAACCR. This agreement allows the MCR to conduct interstate data exchanges with registries that have also signed the agreement. As of May 2018, there are 54 registries that are participating in this agreement.

Funding

The MCR first received funding from NPCR in 1996. The MCR has since received yearly funding from the NPCR to support MCR efforts towards the collection of timely, complete, and accurate data. Other funding sources include the Cigarette Restitution Fund and Maryland State general funds.
B. MCR Operations

The MCR is composed of two entities:

i. A central office, located in the Center for Cancer Prevention and Control at the Maryland Department of Health (MDH), which has administrative, technical, analytical, fiscal, and custodial oversight of MCR.

ii. A subcontractor collects and processes all cancer reports, and performs data quality assurance and database management.

C. Organization of this Report

This report provides 2015 cancer incidence and mortality statistics for the State of Maryland. Data tables include counts for major cancer sites and age-adjusted incidence and mortality rates by year, site, gender, and race for Maryland and its counties. The 2015 Incidence and Mortality Report includes County Data Pages that summarize data for leading cancer sites in each county.

This report is also available on the MCR website at: https://phpa.health.maryland.gov/cancer/Pages/surv_data-reports.aspx.

III. DATA COLLECTION AND MANAGEMENT

A. Reporting Facilities

This report presents data collected from 53 Maryland hospitals, 12 radiation treatment centers, 32 laboratories, 72 ambulatory surgery centers, 62 physicians, and central cancer registries from 15 states and the District of Columbia. Each facility is required to submit cancer reports on all new cancer cases to the MCR.

B. Cancer Case Reporting and Definition

The MCR is the source for cancer incidence (new cases) data presented in this report. Its database contains two types of tumor cases:

i. *Invasive cancers:* This includes all malignant cancers at any site (except for non-genital basal and squamous cell carcinoma of skin), and *in situ* cancers of the urinary bladder diagnosed in Maryland residents between January 1, 2015 and December 31, 2015. (American Cancer Society (ACS) criteria)

ii. *Benign and in situ tumors:* These are tumors the MDH considers important for the review and evaluation of state cancer control programs, but are not included in this report.

The ACS criteria are also used for incidence calculations by the National Cancer Institute’s Surveillance Epidemiology End Results Program (SEER), the American College of Surgeons, and NAACCR.
Cancer sites are grouped according to the conventions of the SEER Program using the *International Classification of Disease, Third Edition (ICD-O-3)* by the World Health Organization and are shown in *Table A: International Classification of Diseases for Oncology, Third Edition (ICD-O-3) and ICD-10 Codes Used to Derive MCR Incidence and Mortality Cancer Data.*

Only new cases diagnosed among Maryland residents in 2015 are included in the analysis.

<table>
<thead>
<tr>
<th>Site</th>
<th>ICD-O-3 Codes Used to Derive Incidence Data</th>
<th>Incidence Histology</th>
<th>ICD-10 Codes Used to Derive Mortality Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>All sites</td>
<td>C00.0--C80.9</td>
<td>Includes all invasive cancers of all sites except --excludes basal and squamous cell skin cancers; Includes in situ cancer of the urinary bladder</td>
<td>C00.0-C97, D09.0</td>
</tr>
<tr>
<td>Brain and Other Nervous System</td>
<td>C70.0--C72.9</td>
<td>Excludes codes 9050-9055, 9140, and 9590-9989</td>
<td>C70.0-C72.9</td>
</tr>
<tr>
<td>Cervix</td>
<td>C53.0--C53.9</td>
<td>Excludes codes 9050-9055, 9140, and 9590-9989</td>
<td>C53.0-C53.9</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>C18.0--C20.9, C26.0</td>
<td>Excludes codes 9050-9055, 9140, and 9590-9989</td>
<td>C18.0-C20.9, C26.0</td>
</tr>
<tr>
<td>Corpus and Uterus NOS</td>
<td>C54.0--C54.9, C55.9</td>
<td>Excludes codes 9050-9055, 9140, and 9590-9989</td>
<td>C54.0-C54.9, C55</td>
</tr>
<tr>
<td>Esophagus</td>
<td>C15.0--C15.9</td>
<td>Excludes codes 9050-9055, 9140, and 9590-9989</td>
<td>C15.0-C15.9</td>
</tr>
<tr>
<td>Female Breast</td>
<td>C50.0--C50.9</td>
<td>Excludes codes 9050-9055, 9140, and 9590-9989</td>
<td>C50.0-C50.9</td>
</tr>
<tr>
<td>Hodgkins Lymphoma</td>
<td>C00.0--C80.9</td>
<td>Includes codes 9650-9667</td>
<td>C81.0-C81.9</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>C64.9, C65.9</td>
<td>Excludes codes 9050-9055, 9140, and 9590-9989</td>
<td>C64.1-C64.9, C65.1-C64.9</td>
</tr>
<tr>
<td>Larynx</td>
<td>C32.0--C32.9</td>
<td>Excludes codes 9050-9055, 9140, and 9590-9989</td>
<td>C32.0-C32.9</td>
</tr>
<tr>
<td>Site</td>
<td>Incidence Topography (Site)</td>
<td>Incidence Histology</td>
<td>CDC Wonder Site Selections</td>
</tr>
<tr>
<td>-----------------------------------------</td>
<td>-----------------------------</td>
<td>---------------------</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td>Leukemia</td>
<td>C00.0--C80.9</td>
<td>Includes codes 9733, 9742, 9800, 9801, 9805, 9820, 9826, 9831-9837, 9840, 9860, 9861, 9863, 9866, 9867, 9870-9876, 9891, 9895-9897, 9910, 9920, 9930, 9931, 9940, 9945, 9946, 9948, 9963, 9964</td>
<td>C91.0-C91.9, C92.0-C92.9, C93.0-C93.9, C94.0-C94.7, C95.0-C95.9</td>
</tr>
<tr>
<td></td>
<td>C42.0, C42.1, C42.4</td>
<td>Includes codes 9823, 9827</td>
<td></td>
</tr>
<tr>
<td>Liver and Intrahepatic Bile Duct</td>
<td>C22.0, C22.1</td>
<td>Excludes codes 9050-9055, 9140, and 9590-9989</td>
<td>C22.0-C22.9</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>C34.0--C34.9</td>
<td>Excludes codes 9050-9055, 9140, and 9590-9989</td>
<td>C34.0-C34.9</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td>C42.1, C42.0, C42.4</td>
<td>Includes codes 9731-9732, 9734</td>
<td>C90.0</td>
</tr>
<tr>
<td>Myeloma</td>
<td></td>
<td></td>
<td>C88.0-C88.9, C90.0-C90.3</td>
</tr>
<tr>
<td>Myelodysplastic Syndromes</td>
<td>C42.1</td>
<td>Includes codes 9980,9982-9987,9989,9991,9992</td>
<td>D46.0–D46.9</td>
</tr>
<tr>
<td>Non-Hodgkins Lymphoma</td>
<td>C00.0--C80.9</td>
<td>Includes codes 9590-9596, 9670-9671, 9673, 9675, 9678-9680, 9684, 9687, 9689-9691,9695,9698-9702,9705,9708-9709,9714-9719,9727-9729</td>
<td>C82.0-C82.9, C83.0-C83.9, C84.0-C84.5, C85.0-C85.9</td>
</tr>
<tr>
<td></td>
<td>C00.0--C80.9 excluding codes C42.0, C42.1, C42.2</td>
<td>Includes codes 9823, 9827</td>
<td></td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>C00.0--C14.8</td>
<td>Excludes codes 9050-9055, 9140, and 9590-9989</td>
<td>C00.0-C14.8</td>
</tr>
<tr>
<td>Ovary</td>
<td>C56.9</td>
<td>Excludes codes 9050-9055, 9140, and 9590-9989</td>
<td>C56.1–C56.9</td>
</tr>
<tr>
<td>Pancreas</td>
<td>C25.0--C25.9</td>
<td>Excludes codes 9050-9055, 9140, and 9590-9989</td>
<td>C25.0-C25.9</td>
</tr>
<tr>
<td>Prostate</td>
<td>C61.9</td>
<td>Excludes codes 9050-9055, 9140, and 9590-9989</td>
<td>C61</td>
</tr>
<tr>
<td>Skin Melanoma</td>
<td>C44.0--C44.9</td>
<td>Includes codes 8720-8790</td>
<td>C43.0–C43.9</td>
</tr>
<tr>
<td>Stomach</td>
<td>C16.0--C16.9</td>
<td>Excludes codes 9050-9055, 9140, and 9590-9989</td>
<td>C16.0-C16.9</td>
</tr>
<tr>
<td>Testis</td>
<td>C62.0--C62.9</td>
<td>Excludes codes 9050-9055, 9140, and 9590-9989</td>
<td>C62.0–C62.9</td>
</tr>
<tr>
<td>Thyroid</td>
<td>C73.9</td>
<td>Excludes codes 9050-9055, 9140, and 9590-9989</td>
<td>C73</td>
</tr>
<tr>
<td>Urinary Bladder (includes in situ and malignant)</td>
<td>C67.0--C67.9</td>
<td>Excludes codes 9050-9055, 9140, and 9590-9989</td>
<td>C67.0-C67.9, D09.0</td>
</tr>
</tbody>
</table>
C. Registry Certification

Every year, NAACCR evaluates MCR data for completeness, quality, and timeliness. In 2015, MCR’s incidence data received NAACCR gold certification for all measures, indicating that data submitted were at least 95% complete. MCR’s 2011 – 2015 incidence data also met NPCR National Data Quality Standard and U.S. Cancer Statistics Publication Standard.

D. Quality Control and Quality Assurance (QC/QA)

The MCR conducts two major activities to maintain quality control and assurance of information received: 1) intra- and inter-record edits of cancer case reports, and 2) yearly audits, or case finding review and re-abstracting of a sample of records from selected reporting facilities. The MCR quality control/quality assurance program also provides the following components for case finding data completeness:

i. A review of death certificate data to identify additional cancer cases among deceased Maryland residents who were not previously reported to the MCR, and

ii. Follow back with the ordering physician about cases reported by laboratories to obtain additional demographic, clinical, and treatment data.

E. Data Confidentiality

MDH regards data received, processed, and reported to or by the MCR confidential, and data are secured from unauthorized access and disclosure. MCR manages and releases information in accordance with the laws and regulations established for and by the State of Maryland as set forth in the Md. Code Ann., Health-General §§ 18-203 and 204, the Code of Maryland Regulations 10.14.01, Cancer Registry and policies available at: https://phpa.health.maryland.gov/cancer/Pages/mcr_regs.aspx.

IV. DATA CHARTS

The data charts in this report present 2015 cancer incidence and mortality by cancer type, gender, and race for the State of Maryland. The County Data Pages contain 2015 counts of incidence and mortality for all cancer sites, 2011 - 2015 incidence and mortality rates for the top five cancers the top five cancer incidence and mortality rates by gender and race, and the distribution of the stage at diagnosis for the top five cancers (2011-2015). All tables and charts should be reviewed with caution as changes in small numbers can lead to wide variations in rates. Confidence intervals are included with rates in the state tables to help guide interpretation. In accordance with the MCR Data Use Manual and Procedures, this report presents data in aggregate.
2015
Maryland Cancer Incidence Cases by Selected Site, Race, and Gender
## Table I: Cancer Sites and All Sites Combined for Maryland:
Count, Age-Adjusted Incidence Rates, and 95% Confidence Intervals by Gender and Race

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>All Races*** 2015</th>
<th>All Genders*** 2015</th>
<th>African-American</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Count</td>
<td>Rate</td>
<td>Lower CI</td>
</tr>
<tr>
<td>All Sites</td>
<td>31,001</td>
<td>449.3</td>
<td>444.2</td>
</tr>
<tr>
<td>Brain and Other Central Nervous System</td>
<td>363</td>
<td>5.6</td>
<td>5.0</td>
</tr>
<tr>
<td>Cervix</td>
<td>228</td>
<td>6.7</td>
<td>5.9</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>2,444</td>
<td>35.9</td>
<td>34.5</td>
</tr>
<tr>
<td>Esophagus</td>
<td>339</td>
<td>4.8</td>
<td>4.3</td>
</tr>
<tr>
<td>Female Breast (Malignant Only)</td>
<td>4,876</td>
<td>131.4</td>
<td>127.6</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>169</td>
<td>2.8</td>
<td>2.4</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>1,045</td>
<td>15.1</td>
<td>14.2</td>
</tr>
<tr>
<td>Larynx</td>
<td>183</td>
<td>2.5</td>
<td>2.1</td>
</tr>
<tr>
<td>Leukemia</td>
<td>772</td>
<td>11.6</td>
<td>10.8</td>
</tr>
<tr>
<td>Liver and Intrahepatic Bile Duct</td>
<td>591</td>
<td>8.0</td>
<td>7.4</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>3,812</td>
<td>55.5</td>
<td>53.7</td>
</tr>
<tr>
<td>Melanoma</td>
<td>1,715</td>
<td>25.5</td>
<td>24.3</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td>524</td>
<td>7.7</td>
<td>7.0</td>
</tr>
<tr>
<td>Myelodysplastic Syndrome</td>
<td>239</td>
<td>3.6</td>
<td>3.2</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>1,107</td>
<td>16.4</td>
<td>15.4</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>796</td>
<td>11.1</td>
<td>10.3</td>
</tr>
<tr>
<td>Ovary</td>
<td>439</td>
<td>11.9</td>
<td>10.7</td>
</tr>
<tr>
<td>Pancreas</td>
<td>902</td>
<td>13.0</td>
<td>12.2</td>
</tr>
<tr>
<td>Prostate</td>
<td>4,063</td>
<td>120.6</td>
<td>116.8</td>
</tr>
<tr>
<td>Stomach</td>
<td>459</td>
<td>6.6</td>
<td>6.0</td>
</tr>
<tr>
<td>Testis</td>
<td>134</td>
<td>4.7</td>
<td>4.3</td>
</tr>
<tr>
<td>Thyroid</td>
<td>911</td>
<td>14.2</td>
<td>13.3</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>1,472</td>
<td>21.7</td>
<td>20.6</td>
</tr>
<tr>
<td>Uterus</td>
<td>1,123</td>
<td>28.7</td>
<td>27.0</td>
</tr>
</tbody>
</table>

*All Races include other specified, unspecified and unknown race

**All Genders include male, female, hermaphrodite, transsexual and unknown(unspecified)

Rates are per 100,000 and are age-adjusted to the 2000 U.S. Standard Population

<6 = case counts of 1-5 are suppressed per MDH/MCR Data Use Policy

** Rates based on case counts of 1-15 are suppressed per MDH/MCR Data Use Policy

Source: Data as of January 03, 2018 Maryland Cancer Registry
<table>
<thead>
<tr>
<th>Cancer Sites and All Sites Combined for Maryland: Count, Age-Adjusted Incidence Rates, and 95% Confidence Intervals by Gender and Race (Continued)</th>
</tr>
</thead>
</table>

**All Genders*** 2015

<table>
<thead>
<tr>
<th>All Sites</th>
<th>1,129</th>
<th>258.5</th>
<th>243.2</th>
<th>274.5</th>
<th>917</th>
<th>287.6</th>
<th>266.9</th>
<th>309.3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain and Other Central Nervous System</td>
<td>14 **</td>
<td>** **</td>
<td>**</td>
<td>20</td>
<td>5.2</td>
<td>2.9</td>
<td>8.5</td>
<td></td>
</tr>
<tr>
<td>Cervix</td>
<td>12 **</td>
<td>** **</td>
<td>**</td>
<td>21</td>
<td>10.5</td>
<td>6.1</td>
<td>16.6</td>
<td></td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>104</td>
<td>23.5</td>
<td>19.1</td>
<td>28.7</td>
<td>69</td>
<td>21.8</td>
<td>16.4</td>
<td>28.2</td>
</tr>
<tr>
<td>Esophagus</td>
<td>7 **</td>
<td>** **</td>
<td>**</td>
<td>&lt;6</td>
<td>** **</td>
<td>**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female Breast (Malignant Only)</td>
<td>225</td>
<td>89.3</td>
<td>77.7</td>
<td>102.0</td>
<td>154</td>
<td>82.4</td>
<td>69.1</td>
<td>97.4</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>12 **</td>
<td>** **</td>
<td>**</td>
<td>10</td>
<td>** **</td>
<td>**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>23</td>
<td>5.4</td>
<td>3.4</td>
<td>8.1</td>
<td>26</td>
<td>8.3</td>
<td>5.1</td>
<td>12.5</td>
</tr>
<tr>
<td>Larynx</td>
<td>&lt;6 **</td>
<td>** **</td>
<td>**</td>
<td>&lt;6</td>
<td>** **</td>
<td>**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukemia</td>
<td>26</td>
<td>6.1</td>
<td>4.0</td>
<td>9.1</td>
<td>39</td>
<td>9.5</td>
<td>6.3</td>
<td>13.7</td>
</tr>
<tr>
<td>Liver and Intrahepatic Bile Duct</td>
<td>35</td>
<td>8.4</td>
<td>5.8</td>
<td>11.9</td>
<td>25</td>
<td>8.0</td>
<td>4.9</td>
<td>12.1</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>90</td>
<td>22.2</td>
<td>17.7</td>
<td>27.5</td>
<td>64</td>
<td>26.5</td>
<td>20.0</td>
<td>34.2</td>
</tr>
<tr>
<td>Melanoma</td>
<td>&lt;6 **</td>
<td>** **</td>
<td>**</td>
<td>17</td>
<td>5.8</td>
<td>3.1</td>
<td>9.6</td>
<td></td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td>8 **</td>
<td>** **</td>
<td>**</td>
<td>14</td>
<td>** **</td>
<td>**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myelodysplastic Syndrome</td>
<td>7 **</td>
<td>** **</td>
<td>**</td>
<td>&lt;6</td>
<td>** **</td>
<td>**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>47</td>
<td>12.1</td>
<td>8.8</td>
<td>16.1</td>
<td>43</td>
<td>12.8</td>
<td>8.8</td>
<td>17.7</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>33</td>
<td>7.3</td>
<td>5.0</td>
<td>10.4</td>
<td>15</td>
<td>** **</td>
<td>**</td>
<td></td>
</tr>
<tr>
<td>Ovary</td>
<td>24</td>
<td>9.3</td>
<td>5.9</td>
<td>13.9</td>
<td>15</td>
<td>** **</td>
<td>**</td>
<td></td>
</tr>
<tr>
<td>Pancreas</td>
<td>42</td>
<td>10.2</td>
<td>7.2</td>
<td>13.9</td>
<td>28</td>
<td>10.9</td>
<td>6.8</td>
<td>16.1</td>
</tr>
<tr>
<td>Prostate</td>
<td>144</td>
<td>71.5</td>
<td>59.9</td>
<td>84.6</td>
<td>92</td>
<td>78.8</td>
<td>61.7</td>
<td>98.8</td>
</tr>
<tr>
<td>Stomach</td>
<td>30</td>
<td>7.8</td>
<td>5.2</td>
<td>11.2</td>
<td>29</td>
<td>9.5</td>
<td>6.1</td>
<td>14.0</td>
</tr>
<tr>
<td>Testis</td>
<td>0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>11</td>
<td>** **</td>
<td>**</td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>89</td>
<td>18.1</td>
<td>14.5</td>
<td>22.4</td>
<td>58</td>
<td>12.9</td>
<td>9.5</td>
<td>17.1</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>29</td>
<td>7.9</td>
<td>5.3</td>
<td>11.5</td>
<td>23</td>
<td>9.9</td>
<td>6.0</td>
<td>15.1</td>
</tr>
<tr>
<td>Uterus</td>
<td>43</td>
<td>16.7</td>
<td>12.0</td>
<td>22.6</td>
<td>41</td>
<td>23.5</td>
<td>16.4</td>
<td>32.3</td>
</tr>
</tbody>
</table>

*All Races include other specified, unspecified and unknown race

***All Genders include male, female, hermaphrodite, transsexual and unknown(unspecified)

Rates are per 100,000 and are age-adjusted to the 2000 U.S. Standard Population

<6 = case counts of 1-5 are suppressed per MDH/MCR Data Use Policy

** Rates based on case counts of 1-15 are suppressed per MDH/MCR Data Use Policy

****Other includes Asian Pacific Islander, American Indian and Alaskan Native, does not include unspecified and unknown races

Source: Data as of January 03, 2018 Maryland Cancer Registry
### Table 2: Cancer Sites and All Sites Combined for Maryland: Count, Age-Adjusted Incidence Rates, and 95% Confidence Intervals by Gender and Race for Males

<table>
<thead>
<tr>
<th></th>
<th>All Races*</th>
<th></th>
<th></th>
<th></th>
<th>White</th>
<th></th>
<th></th>
<th></th>
<th>African-American</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Count</td>
<td>Rate</td>
<td>Lower CI</td>
<td>Upper CI</td>
<td>Count</td>
<td>Rate</td>
<td>Lower CI</td>
<td>Upper CI</td>
<td>Count</td>
<td>Rate</td>
<td>Lower CI</td>
</tr>
<tr>
<td>All Sites</td>
<td>15,234</td>
<td>488.9</td>
<td>481.0</td>
<td>497.0</td>
<td>10,585</td>
<td>493.5</td>
<td>483.8</td>
<td>503.2</td>
<td>4,012</td>
<td>512.4</td>
<td>495.5</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>206</td>
<td>6.7</td>
<td>5.8</td>
<td>7.8</td>
<td>156</td>
<td>7.6</td>
<td>6.4</td>
<td>8.9</td>
<td>34</td>
<td>4.1</td>
<td>2.8</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>93</td>
<td>3.1</td>
<td>2.5</td>
<td>3.9</td>
<td>54</td>
<td>2.9</td>
<td>2.1</td>
<td>3.8</td>
<td>31</td>
<td>3.7</td>
<td>2.4</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>648</td>
<td>20.6</td>
<td>19.0</td>
<td>22.3</td>
<td>461</td>
<td>21.3</td>
<td>19.3</td>
<td>23.4</td>
<td>169</td>
<td>21.7</td>
<td>18.3</td>
</tr>
<tr>
<td>Larynx</td>
<td>134</td>
<td>4.1</td>
<td>3.4</td>
<td>4.9</td>
<td>90</td>
<td>4.1</td>
<td>3.3</td>
<td>5.1</td>
<td>41</td>
<td>4.9</td>
<td>3.4</td>
</tr>
<tr>
<td>Melanoma</td>
<td>1,034</td>
<td>34.3</td>
<td>32.2</td>
<td>36.6</td>
<td>1,012</td>
<td>48.2</td>
<td>45.2</td>
<td>51.3</td>
<td>13</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td>251</td>
<td>8.4</td>
<td>7.4</td>
<td>9.5</td>
<td>139</td>
<td>6.7</td>
<td>5.6</td>
<td>8.0</td>
<td>106</td>
<td>14.7</td>
<td>11.8</td>
</tr>
<tr>
<td>Myelodysplastic Syndrome</td>
<td>132</td>
<td>4.8</td>
<td>4.0</td>
<td>5.8</td>
<td>112</td>
<td>5.7</td>
<td>4.6</td>
<td>6.8</td>
<td>15</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>601</td>
<td>19.8</td>
<td>18.2</td>
<td>21.5</td>
<td>453</td>
<td>21.6</td>
<td>19.6</td>
<td>23.7</td>
<td>121</td>
<td>14.8</td>
<td>12.1</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>569</td>
<td>17.1</td>
<td>15.7</td>
<td>18.6</td>
<td>418</td>
<td>18.3</td>
<td>16.6</td>
<td>20.2</td>
<td>126</td>
<td>15.2</td>
<td>12.4</td>
</tr>
<tr>
<td>Pancreas</td>
<td>466</td>
<td>15.1</td>
<td>13.7</td>
<td>16.6</td>
<td>305</td>
<td>14.0</td>
<td>12.4</td>
<td>15.7</td>
<td>134</td>
<td>18.0</td>
<td>14.9</td>
</tr>
<tr>
<td>Prostate</td>
<td>4,063</td>
<td>120.6</td>
<td>116.8</td>
<td>124.5</td>
<td>2,293</td>
<td>98.5</td>
<td>94.4</td>
<td>102.7</td>
<td>1,577</td>
<td>188.4</td>
<td>178.6</td>
</tr>
<tr>
<td>Stomach</td>
<td>282</td>
<td>9.2</td>
<td>8.1</td>
<td>10.3</td>
<td>175</td>
<td>8.0</td>
<td>6.8</td>
<td>9.3</td>
<td>80</td>
<td>11.5</td>
<td>9.0</td>
</tr>
<tr>
<td>Testis</td>
<td>134</td>
<td>4.7</td>
<td>3.9</td>
<td>5.5</td>
<td>120</td>
<td>6.9</td>
<td>5.7</td>
<td>8.2</td>
<td>10</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Thyroid</td>
<td>201</td>
<td>6.5</td>
<td>5.6</td>
<td>7.5</td>
<td>144</td>
<td>7.1</td>
<td>6.0</td>
<td>8.4</td>
<td>40</td>
<td>4.9</td>
<td>3.5</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>1,116</td>
<td>38.6</td>
<td>36.3</td>
<td>41.0</td>
<td>930</td>
<td>45.0</td>
<td>42.1</td>
<td>48.1</td>
<td>162</td>
<td>23.6</td>
<td>19.8</td>
</tr>
</tbody>
</table>

*All Races Include other specified, unspecified and unknown race

Rates are per 100,000 and are age-adjusted to the 2000 U.S. Standard Population

<6 = case counts of 1-5 are suppressed per MDH/MCR Data Use Policy

** Rates based on case counts of 1-15 are suppressed per MDH/MCR Data Use Policy

Source: Data as of January 03, 2018 Maryland Cancer Registry
### Table I.2: Cancer Sites and All Sites Combined for Maryland: Count, Age-Adjusted Incidence Rates, and 95% Confidence Intervals by Gender and Race for Males (Continued)

<table>
<thead>
<tr>
<th>Cancer Site and Site Group</th>
<th>Count</th>
<th>Rate</th>
<th>Lower CI</th>
<th>Upper CI</th>
<th>Count</th>
<th>Rate</th>
<th>Lower CI</th>
<th>Upper CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>500</td>
<td>258.2</td>
<td>235.1</td>
<td>282.8</td>
<td>370</td>
<td>278.7</td>
<td>245.7</td>
<td>314.3</td>
</tr>
<tr>
<td>Brain and Other Central Nervous System</td>
<td>9</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>12</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>61</td>
<td>30.6</td>
<td>23.2</td>
<td>39.7</td>
<td>37</td>
<td>23.8</td>
<td>15.6</td>
<td>34.6</td>
</tr>
<tr>
<td>Esophagus</td>
<td>&lt;6</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;6</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>8</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;6</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>16</td>
<td>7.9</td>
<td>4.4</td>
<td>13.0</td>
<td>12</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Larynx</td>
<td>&lt;6</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;6</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Leukemia</td>
<td>16</td>
<td>7.5</td>
<td>4.2</td>
<td>12.4</td>
<td>16</td>
<td>9.2</td>
<td>4.2</td>
<td>16.9</td>
</tr>
<tr>
<td>Liver and Intrahepatic Bile Duct</td>
<td>23</td>
<td>11.8</td>
<td>7.3</td>
<td>18.0</td>
<td>16</td>
<td>9.9</td>
<td>5.2</td>
<td>17.0</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>52</td>
<td>29.2</td>
<td>21.5</td>
<td>38.6</td>
<td>24</td>
<td>25.7</td>
<td>15.7</td>
<td>38.8</td>
</tr>
<tr>
<td>Melanoma</td>
<td>&lt;6</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;6</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td>&lt;6</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>6</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Myelodysplastic Syndrome</td>
<td>&lt;6</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;6</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>19</td>
<td>10.6</td>
<td>6.2</td>
<td>16.7</td>
<td>25</td>
<td>15.6</td>
<td>9.0</td>
<td>24.7</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>20</td>
<td>10.0</td>
<td>6.0</td>
<td>15.7</td>
<td>10</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Pancreas</td>
<td>26</td>
<td>13.3</td>
<td>8.5</td>
<td>19.6</td>
<td>12</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Prostate</td>
<td>144</td>
<td>71.5</td>
<td>59.9</td>
<td>84.6</td>
<td>92</td>
<td>78.8</td>
<td>61.7</td>
<td>98.8</td>
</tr>
<tr>
<td>Stomach</td>
<td>19</td>
<td>11.6</td>
<td>6.8</td>
<td>18.1</td>
<td>14</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Testis</td>
<td>0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>11</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Thyroid</td>
<td>16</td>
<td>6.8</td>
<td>3.9</td>
<td>11.1</td>
<td>&lt;6</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>19</td>
<td>11.3</td>
<td>6.6</td>
<td>17.7</td>
<td>17</td>
<td>19.5</td>
<td>10.6</td>
<td>31.8</td>
</tr>
</tbody>
</table>

*All Races include other specified, unspecified and unknown race

Rates are per 100,000 and are age-adjusted to the 2000 U.S. Standard Population

<6 = case counts of 1-5 are suppressed per MDH/MCR Data Use Policy

** Rates based on case counts of 1-15 are suppressed per MDH/MCR Data Use Policy

****Other includes Asian Pacific Islander, American Indian and Alaskan Native, does not include unspecified and unknown races

Source: Data as of January 03, 2018 Maryland Cancer Registry
Table I 3: Cancer Sites and All Sites Combined for Maryland: Count, Age-Adjusted Incidence Rates, and 95% Confidence Intervals by Gender and Race for Females

<table>
<thead>
<tr>
<th>Cancer Sites</th>
<th>All Races*</th>
<th>White</th>
<th>African-American</th>
</tr>
</thead>
<tbody>
<tr>
<td>Count, Rate, Lower CI, Upper CI</td>
<td>Count, Rate, Lower CI, Upper CI</td>
<td>Count, Rate, Lower CI, Upper CI</td>
<td></td>
</tr>
<tr>
<td>All Sites</td>
<td>15,765</td>
<td>423.8</td>
<td>417.1, 430.7</td>
</tr>
<tr>
<td>Brain and Other Central Nervous System</td>
<td>157</td>
<td>4.6</td>
<td>3.9, 5.4</td>
</tr>
<tr>
<td>Cervix</td>
<td>228</td>
<td>6.7</td>
<td>5.9, 7.7</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>1,217</td>
<td>32.3</td>
<td>30.5, 34.3</td>
</tr>
<tr>
<td>Esophagus</td>
<td>88</td>
<td>2.2</td>
<td>1.8, 2.8</td>
</tr>
<tr>
<td>Female Breast (Malignant Only)</td>
<td>4,876</td>
<td>131.4</td>
<td>127.6, 135.2</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>76</td>
<td>2.5</td>
<td>1.9, 3.1</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>397</td>
<td>10.7</td>
<td>9.6, 11.8</td>
</tr>
<tr>
<td>Larynx</td>
<td>49</td>
<td>1.2</td>
<td>0.9, 1.6</td>
</tr>
<tr>
<td>Leukemia</td>
<td>364</td>
<td>9.9</td>
<td>8.9, 11.1</td>
</tr>
<tr>
<td>Liver and Intrahepatic Bile Duct</td>
<td>176</td>
<td>4.5</td>
<td>3.9, 5.3</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>1,934</td>
<td>50.4</td>
<td>48.2, 52.8</td>
</tr>
<tr>
<td>Melanoma</td>
<td>680</td>
<td>19.2</td>
<td>17.7, 20.7</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td>273</td>
<td>7.2</td>
<td>6.3, 8.1</td>
</tr>
<tr>
<td>Myelodysplastic Syndrome</td>
<td>107</td>
<td>2.8</td>
<td>2.3, 3.4</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>505</td>
<td>13.7</td>
<td>12.5, 15.0</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>227</td>
<td>5.9</td>
<td>5.2, 6.8</td>
</tr>
<tr>
<td>Ovary</td>
<td>439</td>
<td>11.9</td>
<td>10.7, 13.1</td>
</tr>
<tr>
<td>Pancreas</td>
<td>436</td>
<td>11.4</td>
<td>10.3, 12.6</td>
</tr>
<tr>
<td>Stomach</td>
<td>177</td>
<td>4.7</td>
<td>4.0, 5.4</td>
</tr>
<tr>
<td>Thyroid</td>
<td>710</td>
<td>21.4</td>
<td>19.8, 23.1</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>356</td>
<td>9.3</td>
<td>8.3, 10.3</td>
</tr>
<tr>
<td>Uterus</td>
<td>1,123</td>
<td>28.7</td>
<td>27.0, 30.5</td>
</tr>
</tbody>
</table>

*All Races include other specified, unspecified and unknown race
**Both Genders include male, female, hermaphrodite, transsexual and unknown(unspecified)
Rates are per 100,000 and are age-adjusted to the 2000 U.S. Standard Population
<6 = case counts of 1-5 are suppressed per MDH/MCR Data Use Policy
2-5 = case counts of 1-15 are suppressed per MDH/MCR Data Use Policy
Source: Data as of January 03, 2018 Maryland Cancer Registry
<table>
<thead>
<tr>
<th>Cancer Sites and All Sites Combined for Maryland: Count, Age-Adjusted Incidence Rates, and 95% Confidence Intervals by Gender and Race for Females (Continued)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>All Sites</th>
<th>Count</th>
<th>Rate</th>
<th>Lower CI</th>
<th>Upper CI</th>
<th>Count</th>
<th>Rate</th>
<th>Lower CI</th>
<th>Upper CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain and Other Central Nervous System</td>
<td>&lt;6</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>8</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Cervix</td>
<td>12</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>21</td>
<td>10.5</td>
<td>6.1</td>
<td>16.6</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>43</td>
<td>17.7</td>
<td>12.7</td>
<td>24.1</td>
<td>32</td>
<td>19.8</td>
<td>13.1</td>
<td>28.3</td>
</tr>
<tr>
<td>Esophagus</td>
<td>&lt;6</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Female Breast (Malignant Only)</td>
<td>225</td>
<td>89.3</td>
<td>77.7</td>
<td>102.0</td>
<td>154</td>
<td>82.4</td>
<td>69.1</td>
<td>97.4</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>&lt;6</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;6</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>7</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>14</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Larynx</td>
<td>0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>&lt;6</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Leukemia</td>
<td>10</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>23</td>
<td>10.5</td>
<td>6.3</td>
<td>16.4</td>
</tr>
<tr>
<td>Liver and Intrahepatic Bile Duct</td>
<td>12</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>9</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>38</td>
<td>16.6</td>
<td>11.7</td>
<td>23.0</td>
<td>40</td>
<td>27.7</td>
<td>19.4</td>
<td>38.0</td>
</tr>
<tr>
<td>Melanoma</td>
<td>&lt;6</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>13</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td>&lt;6</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>8</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Myelodysplastic Syndrome</td>
<td>&lt;6</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>28</td>
<td>13.3</td>
<td>8.7</td>
<td>19.3</td>
<td>18</td>
<td>10.4</td>
<td>5.9</td>
<td>16.7</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>13</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;6</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Ovary</td>
<td>24</td>
<td>9.3</td>
<td>5.9</td>
<td>13.9</td>
<td>15</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Pancreas</td>
<td>16</td>
<td>7.4</td>
<td>4.1</td>
<td>12.1</td>
<td>16</td>
<td>10.3</td>
<td>5.6</td>
<td>17.1</td>
</tr>
<tr>
<td>Stomach</td>
<td>11</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>15</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Thyroid</td>
<td>73</td>
<td>28.2</td>
<td>22.0</td>
<td>35.6</td>
<td>53</td>
<td>24.0</td>
<td>17.6</td>
<td>31.9</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>10</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>6</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Uterus</td>
<td>43</td>
<td>16.7</td>
<td>12.0</td>
<td>22.6</td>
<td>41</td>
<td>23.5</td>
<td>16.4</td>
<td>32.3</td>
</tr>
</tbody>
</table>

*All Races include other specified, unspecified and unknown race*

*Rates are per 100,000 and are age-adjusted to the 2000 U.S. Standard Population*

<6 = case counts of 1-5 are suppressed per MDH/MCR Data Use Policy

** Rates based on case counts of 1-15 are suppressed per MDH/MCR Data Use Policy

****Other includes Asian Pacific Islander, American Indian and Alaskan Native, does not include unspecified and unknown races

Source: Data as of January 03, 2018 Maryland Cancer Registry
2015

Maryland Cancer Mortality Cases by Selected Site, Race, and Gender
<p>| Cancer Sites and All Sites Combined for Maryland: Count, Age-Adjusted Mortality Rates, and 95% Confidence Intervals by Gender and Race |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | <em>All Races</em> | | | | | | | | | | |</p>
<table>
<thead>
<tr>
<th>Count</th>
<th>Rate</th>
<th>Lower CI</th>
<th>Upper CI</th>
<th>Count</th>
<th>Rate</th>
<th>Lower CI</th>
<th>Upper CI</th>
<th>Count</th>
<th>Rate</th>
<th>Lower CI</th>
<th>Upper CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>10,568</td>
<td>155.1</td>
<td>152.1</td>
<td>158.1</td>
<td>7,175</td>
<td>152.2</td>
<td>148.6</td>
<td>155.8</td>
<td>3,065</td>
<td>176.3</td>
<td>169.9</td>
</tr>
<tr>
<td>Brain and Other Central Nervous System</td>
<td>285</td>
<td>4.2</td>
<td>3.7</td>
<td>4.6</td>
<td>230</td>
<td>5.1</td>
<td>4.4</td>
<td>5.7</td>
<td>44</td>
<td>2.4</td>
<td>1.7</td>
</tr>
<tr>
<td>Cervix</td>
<td>69</td>
<td>1.9</td>
<td>1.4</td>
<td>2.4</td>
<td>s</td>
<td>1.5</td>
<td>1.0</td>
<td>2.1</td>
<td>33</td>
<td>3.0</td>
<td>2.1</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>615</td>
<td>13.5</td>
<td>12.6</td>
<td>14.4</td>
<td>603</td>
<td>12.8</td>
<td>11.7</td>
<td>13.8</td>
<td>290</td>
<td>17.3</td>
<td>15.2</td>
</tr>
<tr>
<td>Esophagus</td>
<td>259</td>
<td>3.7</td>
<td>3.2</td>
<td>4.1</td>
<td>203</td>
<td>4.2</td>
<td>3.7</td>
<td>4.8</td>
<td>s</td>
<td>2.8</td>
<td>2.1</td>
</tr>
<tr>
<td>Female Breast (Malignant Only)</td>
<td>825</td>
<td>21.7</td>
<td>20.2</td>
<td>23.3</td>
<td>525</td>
<td>20.5</td>
<td>18.6</td>
<td>22.3</td>
<td>283</td>
<td>26.5</td>
<td>23.4</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>12</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>10</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>241</td>
<td>3.6</td>
<td>3.1</td>
<td>4.0</td>
<td>171</td>
<td>3.7</td>
<td>3.1</td>
<td>4.2</td>
<td>s</td>
<td>4.0</td>
<td>3.1</td>
</tr>
<tr>
<td>Larynx</td>
<td>86</td>
<td>1.2</td>
<td>1.0</td>
<td>1.5</td>
<td>49</td>
<td>1.0</td>
<td>0.7</td>
<td>1.3</td>
<td>s</td>
<td>2.0</td>
<td>1.3</td>
</tr>
<tr>
<td>Leukemia</td>
<td>379</td>
<td>5.8</td>
<td>5.2</td>
<td>6.4</td>
<td>287</td>
<td>6.2</td>
<td>5.5</td>
<td>7.0</td>
<td>77</td>
<td>4.6</td>
<td>3.6</td>
</tr>
<tr>
<td>Liver and Intrahepatic Bile Duct</td>
<td>455</td>
<td>6.3</td>
<td>5.7</td>
<td>6.9</td>
<td>260</td>
<td>5.3</td>
<td>4.6</td>
<td>5.9</td>
<td>173</td>
<td>8.9</td>
<td>7.5</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>2,579</td>
<td>37.6</td>
<td>36.1</td>
<td>39.0</td>
<td>1,817</td>
<td>38.2</td>
<td>36.4</td>
<td>40.0</td>
<td>690</td>
<td>39.7</td>
<td>36.6</td>
</tr>
<tr>
<td>Melanoma</td>
<td>121</td>
<td>1.8</td>
<td>1.5</td>
<td>2.1</td>
<td>112</td>
<td>2.5</td>
<td>2.0</td>
<td>2.9</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td>257</td>
<td>3.9</td>
<td>3.4</td>
<td>4.4</td>
<td>140</td>
<td>3.0</td>
<td>2.5</td>
<td>3.6</td>
<td>107</td>
<td>6.7</td>
<td>5.4</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>342</td>
<td>5.1</td>
<td>4.5</td>
<td>5.6</td>
<td>255</td>
<td>5.4</td>
<td>4.8</td>
<td>6.1</td>
<td>76</td>
<td>4.3</td>
<td>3.3</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>155</td>
<td>2.2</td>
<td>1.9</td>
<td>2.6</td>
<td>107</td>
<td>2.3</td>
<td>1.8</td>
<td>2.7</td>
<td>s</td>
<td>2.3</td>
<td>1.7</td>
</tr>
<tr>
<td>Ovary</td>
<td>247</td>
<td>6.5</td>
<td>5.7</td>
<td>7.3</td>
<td>163</td>
<td>6.5</td>
<td>5.5</td>
<td>7.5</td>
<td>s</td>
<td>7.4</td>
<td>5.8</td>
</tr>
<tr>
<td>Pancreas</td>
<td>807</td>
<td>11.6</td>
<td>10.8</td>
<td>12.5</td>
<td>538</td>
<td>11.2</td>
<td>10.2</td>
<td>12.2</td>
<td>237</td>
<td>13.5</td>
<td>11.7</td>
</tr>
<tr>
<td>Prostate</td>
<td>556</td>
<td>21.0</td>
<td>19.2</td>
<td>22.8</td>
<td>324</td>
<td>16.8</td>
<td>15.0</td>
<td>18.7</td>
<td>215</td>
<td>38.3</td>
<td>32.9</td>
</tr>
<tr>
<td>Stomach</td>
<td>238</td>
<td>3.5</td>
<td>3.0</td>
<td>3.9</td>
<td>131</td>
<td>2.9</td>
<td>2.4</td>
<td>3.4</td>
<td>85</td>
<td>4.9</td>
<td>3.9</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>293</td>
<td>4.4</td>
<td>3.9</td>
<td>4.9</td>
<td>238</td>
<td>5.0</td>
<td>4.4</td>
<td>5.7</td>
<td>s</td>
<td>3.1</td>
<td>2.2</td>
</tr>
<tr>
<td>Uterus</td>
<td>214</td>
<td>5.5</td>
<td>4.7</td>
<td>6.2</td>
<td>111</td>
<td>4.4</td>
<td>3.5</td>
<td>5.2</td>
<td>s</td>
<td>8.4</td>
<td>6.8</td>
</tr>
</tbody>
</table>

*All Races includes White, Black or African American, Asian or Pacific Islander, American Indian or Alaska Native

Rates are per 100,000 and are age-adjusted to the 2000 U.S. Standard Population

<10 = case counts of 0-9 are suppressed per MDH/CDC Data Use Policy
s=Death counts are suppressed to prevent disclosure of data in other cell(s)

** Rates based on case counts of 0-19 are suppressed per MDH/CDC Data Use Policy

Source: CDC Wonder as of February 22, 2018
Table M 1: Cancer Sites and All Sites Combined for Maryland:
Count, Age-Adjusted Mortality Rates, and 95% Confidence Intervals by Gender and Race (Continued)

<table>
<thead>
<tr>
<th>Both Genders 2015</th>
<th><strong>Other</strong></th>
<th>Hispanic Ethnicity (of Any Race)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Count</td>
<td>Rate</td>
</tr>
<tr>
<td>All Sites</td>
<td>328</td>
<td>84.8</td>
</tr>
<tr>
<td>Brain and Other Central Nervous System</td>
<td>11</td>
<td>**</td>
</tr>
<tr>
<td>Cervix</td>
<td>&lt;10</td>
<td>**</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>22</td>
<td>5.4</td>
</tr>
<tr>
<td>Esophagus</td>
<td>&lt;10</td>
<td>**</td>
</tr>
<tr>
<td>Female Breast (Malignant Only)</td>
<td>17</td>
<td>7.7</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>&lt;10</td>
<td>**</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>&lt;10</td>
<td>**</td>
</tr>
<tr>
<td>Larynx</td>
<td>&lt;10</td>
<td>**</td>
</tr>
<tr>
<td>Leukemia</td>
<td>15</td>
<td>**</td>
</tr>
<tr>
<td>Liver and Intrahepatic Bile Duct</td>
<td>22</td>
<td>5.6</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>72</td>
<td>18.1</td>
</tr>
<tr>
<td>Melanoma</td>
<td>&lt;10</td>
<td>**</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td>10</td>
<td>**</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>11</td>
<td>**</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>&lt;10</td>
<td>**</td>
</tr>
<tr>
<td>Ovary</td>
<td>&lt;10</td>
<td>**</td>
</tr>
<tr>
<td>Pancreas</td>
<td>32</td>
<td>7.7</td>
</tr>
<tr>
<td>Prostate</td>
<td>17</td>
<td>**</td>
</tr>
<tr>
<td>Stomach</td>
<td>22</td>
<td>5.8</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>&lt;10</td>
<td>**</td>
</tr>
<tr>
<td>Uterus</td>
<td>&lt;10</td>
<td>**</td>
</tr>
</tbody>
</table>

Rates are per 100,000 and are age-adjusted to the 2000 U.S. Standard Population

<10 = case counts of 0-9 are suppressed per MDH/CDC Data Use Policy

** Rates based on case counts of 0-19 are suppressed per MDH/CDC Data Use Policy

***Other Includes Asian or Pacific Islander and American Indian or Alaska Native

s=Death counts are suppressed to prevent disclosure of data in other cell(s)

Source: CDC Wonder as of February 22, 2018
### Table M 2: Cancer Sites and All Sites Combined for Maryland:
Count, Age-Adjusted Mortality Rates, and 95% Confidence Intervals by Gender and Race

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>*All Races</th>
<th>Male 2015</th>
<th>African-American</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Count</td>
<td>Rate</td>
<td>Lower CI</td>
</tr>
<tr>
<td>All Sites</td>
<td>5,377</td>
<td>183.7</td>
<td>178.7</td>
</tr>
<tr>
<td>Brain and Other Central Nervous System</td>
<td>155</td>
<td>4.9</td>
<td>4.1</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>460</td>
<td>15.7</td>
<td>14.2</td>
</tr>
<tr>
<td>Esophagus</td>
<td>203</td>
<td>6.6</td>
<td>5.7</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>165</td>
<td>5.5</td>
<td>4.7</td>
</tr>
<tr>
<td>Larynx</td>
<td>70</td>
<td>2.3</td>
<td>1.8</td>
</tr>
<tr>
<td>Leukemia</td>
<td>228</td>
<td>8.3</td>
<td>7.2</td>
</tr>
<tr>
<td>Liver and Intrahepatic Bile Duct</td>
<td>316</td>
<td>9.6</td>
<td>8.5</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>1,335</td>
<td>44.9</td>
<td>42.4</td>
</tr>
<tr>
<td>Melanoma</td>
<td>80</td>
<td>2.8</td>
<td>2.2</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td>122</td>
<td>4.4</td>
<td>3.6</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>201</td>
<td>6.9</td>
<td>5.9</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>107</td>
<td>3.5</td>
<td>2.8</td>
</tr>
<tr>
<td>Pancreas</td>
<td>397</td>
<td>13.1</td>
<td>11.8</td>
</tr>
<tr>
<td>Prostate</td>
<td>556</td>
<td>21.0</td>
<td>19.2</td>
</tr>
<tr>
<td>Stomach</td>
<td>140</td>
<td>4.7</td>
<td>3.9</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>223</td>
<td>8.2</td>
<td>7.1</td>
</tr>
</tbody>
</table>

*All Races includes White, Black or African American, Asian or Pacific Islander, American Indian or Alaska Native.

Rates are per 100,000 and are age-adjusted to the 2000 U.S. Standard Population.

<10 = case counts of 0-9 are suppressed per MDH/CDC Data Use Policy.

s=Death counts are suppressed to prevent disclosure of data in other cell(s).

** Rates based on case counts of 0-19 are suppressed per MDH/CDC Data Use Policy.

Source: CDC Wonder as of February 22, 2018.
| Cancer Sites and All Sites Combined for Maryland: Count, Age-Adjusted Mortality Rates, and 95% Confidence Intervals by Gender and Race (Continued) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | **Male 2015** | | | | **Hispanic Ethnicity (of Any Race)** | | | | | | | | | |
| | Count | Rate | Lower CI | Upper CI | Count | Rate | Lower CI | Upper CI |
| All Sites | 182 | 106.9 | 90.7 | 123.0 | 89 | 73.1 | 55.9 | 93.9 |
| Brain and Other Central Nervous System | <10 | ** | ** | ** | <10 | ** | ** | ** |
| Colon and Rectum | 12 | ** | ** | ** | <10 | ** | ** | ** |
| Esophagus | <10 | ** | ** | ** | <10 | ** | ** | ** |
| Hodgkin Lymphoma | <10 | ** | ** | ** | <10 | ** | ** | ** |
| Kidney and Renal Pelvis | <10 | ** | ** | ** | <10 | ** | ** | ** |
| Larynx | <10 | ** | ** | ** | <10 | ** | ** | ** |
| Leukemia | <10 | ** | ** | ** | <10 | ** | ** | ** |
| Liver and Intrahepatic Bile Duct | s | ** | ** | ** | <10 | ** | ** | ** |
| Lung and Bronchus | 42 | 23.8 | 17.0 | 32.6 | 15 | ** | ** | ** |
| Melanoma | <10 | ** | ** | ** | <10 | ** | ** | ** |
| Multiple Myeloma | <10 | ** | ** | ** | <10 | ** | ** | ** |
| Non-Hodgkin Lymphoma | <10 | ** | ** | ** | <10 | ** | ** | ** |
| Oral Cavity and Pharynx | <10 | ** | ** | ** | <10 | ** | ** | ** |
| Pancreas | 18 | ** | ** | ** | <10 | ** | ** | ** |
| Prostate | 17 | ** | ** | ** | <10 | ** | ** | ** |
| Stomach | s | ** | ** | ** | s | ** | ** | ** |
| Urinary Bladder | <10 | ** | ** | ** | <10 | ** | ** | ** |

Rates are per 100,000 and are age-adjusted to the 2000 U.S. Standard Population

<10 = case counts of 0-9 are suppressed per MDH/CDC Data Use Policy

** Rates based on case counts of 0-19 are suppressed per MDH/CDC Data Use Policy

***Other Includes Asian or Pacific Islander and American Indian or Alaska Native

s=Death counts are suppressed to prevent disclosure of data in other cell(s)

Source: CDC Wonder as of February 22, 2018
| Cancer Sites and All Sites Combined for Maryland: |
| Count, Age-Adjusted Mortality Rates, and 95% Confidence Intervals by Gender and Race |

| Table M 3: Cancer Sites and All Sites Combined for Maryland: |
| Count, Age-Adjusted Mortality Rates, and 95% Confidence Intervals by Gender and Race |

<table>
<thead>
<tr>
<th>All Races*</th>
<th>Female 2015</th>
<th>African-American</th>
</tr>
</thead>
<tbody>
<tr>
<td>Count</td>
<td>Rate</td>
<td>Lower CI</td>
</tr>
<tr>
<td>All Sites</td>
<td>5,191</td>
<td>135.1</td>
</tr>
<tr>
<td></td>
<td>1,592</td>
<td>153.5</td>
</tr>
<tr>
<td>Brain and Other Central Nervous System</td>
<td>130</td>
<td>3.5</td>
</tr>
<tr>
<td>Cervix</td>
<td>69</td>
<td>1.9</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>455</td>
<td>11.8</td>
</tr>
<tr>
<td>Esophagus</td>
<td>56</td>
<td>1.4</td>
</tr>
<tr>
<td>Female Breast (Malignant Only)</td>
<td>825</td>
<td>21.7</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>&lt;10</td>
<td>** ** **</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>76</td>
<td>2.1</td>
</tr>
<tr>
<td>Larynx</td>
<td>16</td>
<td>** ** **</td>
</tr>
<tr>
<td>Leukemia</td>
<td>151</td>
<td>4.0</td>
</tr>
<tr>
<td>Liver and Intrahepatic Bile Duct</td>
<td>139</td>
<td>3.6</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>1,244</td>
<td>32.2</td>
</tr>
<tr>
<td>Melanoma</td>
<td>41</td>
<td>1.1</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td>135</td>
<td>3.6</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>141</td>
<td>3.6</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>48</td>
<td>1.3</td>
</tr>
<tr>
<td>Ovary</td>
<td>247</td>
<td>6.5</td>
</tr>
<tr>
<td>Pancreas</td>
<td>410</td>
<td>10.5</td>
</tr>
<tr>
<td>Stomach</td>
<td>98</td>
<td>2.5</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>70</td>
<td>1.8</td>
</tr>
<tr>
<td>Uterus</td>
<td>214</td>
<td>5.5</td>
</tr>
</tbody>
</table>

*All Races Includes White, Black or African American, Asian or Pacific Islander, American Indian or Alaska Native

Rates are per 100,000 and are age-adjusted to the 2000 U.S. Standard Population
<10 = case counts of 0-9 are suppressed per MDH/CDC Data Use Policy
s=Death counts are suppressed to prevent disclosure of data in other cell(s)
** Rates based on case counts of 0-19 are suppressed per MDH/CDC Data Use Policy

Source: CDC Wonder as of February 22, 2018
Table M 3: Cancer Sites and All Sites Combined for Maryland:  
Count, Age-Adjusted Mortality Rates, and 95% Confidence Intervals by Gender and Race (Continued)

<table>
<thead>
<tr>
<th>Site</th>
<th>Count</th>
<th>Rate</th>
<th>Lower CI</th>
<th>Upper CI</th>
<th>Count</th>
<th>Rate</th>
<th>Lower CI</th>
<th>Upper CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>146</td>
<td>67.1</td>
<td>55.9</td>
<td>78.3</td>
<td>117</td>
<td>78.4</td>
<td>63.3</td>
<td>93.5</td>
</tr>
<tr>
<td>Brain and Other Central Nervous System</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Cervix</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>10</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>5</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Esophagus</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Female Breast (Malignant Only)</td>
<td>17</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>14</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Larynx</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Leukemia</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Liver and Intrahepatic Bile Duct</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>30</td>
<td>13.6</td>
<td>9.0</td>
<td>19.7</td>
<td>15</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Melanoma</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Ovary</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Pancreas</td>
<td>14</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>5</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Stomach</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Uterus</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>&lt;10</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
</tbody>
</table>

Rates are per 100,000 and are age-adjusted to the 2000 U.S. Standard Population

<10 = case counts of 0-9 are suppressed per MDH/CDC Data Use Policy

** Rates based on case counts of 0-19 are suppressed per MDH/CDC Data Use Policy

***Other Includes Asian or Pacific Islander and American Indian or Alaska Native

s=Death counts are suppressed to prevent disclosure of data in other cell(s)

Source: CDC Wonder as of February 22, 2018
2015 Maryland Incidence and Mortality
Selected Facts
(Maryland and by County)
This page left blank intentionally
Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Maryland were:
- **Incidence:** 31,001 new cases of all cancer cases
- **Mortality:** 10,568 deaths from cancer

### Top 5 Incidence and Mortality Cancer Rates, 2011-2015

#### Incidence and Mortality Rates by Race and Gender, 2011-2015

#### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

Prepared by the Maryland Cancer Registry (MCR). The MCR is the state's official source for cancer statistics. The MCR collects all new cases of reportable cancer diagnosed/and or treated in Maryland.

* Suppressed rates:
  - Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
  - Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy
  - Other = Asian or Pacific Islander, American Indian, Alaskan Native

** Percentages for cancer staging may not total 100% due to rounding
According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Allegany County were:

**Incidence:** 489 new cases of all cancer cases

**Mortality:** 185 deaths from cancer

### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Local</th>
<th>Regional</th>
<th>Distant</th>
<th>Unstaged</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Breast</td>
<td>64.8%</td>
<td>32.6%</td>
<td>5.3%</td>
<td>0.7%</td>
</tr>
<tr>
<td>Prostate</td>
<td>78.6%</td>
<td>6.6%</td>
<td>5.1%</td>
<td>9.7%</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>24.5%</td>
<td>45.5%</td>
<td>2.3%</td>
<td></td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>27.2%</td>
<td>23.7%</td>
<td>6.0%</td>
<td></td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>83.5%</td>
<td></td>
<td>7.6%</td>
<td>6.7%</td>
</tr>
</tbody>
</table>

Prepared by the Maryland Cancer Registry (MCR). The MCR is the state’s official source for cancer statistics. The MCR collects all new cases of reportable cancer diagnosed/and or treated in Maryland.

* Suppressed rates:
  * Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
  * Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy

Other = Asian or Pacific Islander, American Indian, Alaskan Native

**Percentages for cancer staging may not total 100% due to rounding**
According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Anne Arundel County were:

- **Incidence:** 2,957 new cases of all cancer cases
- **Mortality:** 953 deaths from cancer

### Top 5 Incidence and Morality Cancer Rates, 2011-2015

#### Incidence and Mortality Rates by Race and Gender, 2011-2015

#### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

Prepared by the Maryland Cancer Registry (MCR). The MCR is the state’s official source for cancer statistics. The MCR collects all new cases of reportable cancer diagnosed/and or treated in Maryland.

* Suppressed rates:
  - Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
  - Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy

Other = Asian or Pacific Islander, American Indian, Alaskan Native

**Percentages for cancer staging may not total 100% due to rounding
According to the Maryland Cancer Registry, a total of 31,011 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Baltimore City were:

**Incidence:** 3,177 new cases of all cancer cases

**Mortality:** 1,302 deaths from cancer

### Top 5 Incidence and Mortality Cancer Rates, 2011-2015

#### Incidence and Mortality Rates by Race and Gender, 2011-2015

#### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

Prepared by the Maryland Cancer Registry (MCR). The MCR is the state’s official source for cancer statistics. The MCR collects all new cases of reportable cancer diagnosed/and or treated in Maryland.

* Suppressed rates:
  - Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
  - Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy

Other = Asian or Pacific Islander, American Indian, Alaskan Native

**Percentages for cancer staging may not total 100% due to rounding
According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Baltimore County were:

**Incidence:** 5,024 new cases of all cancer cases

**Mortality:** 1,789 deaths from cancer

### Top 5 Incidence and Mortality Cancer Rates, 2011-2015

<table>
<thead>
<tr>
<th>Race</th>
<th>Incidence</th>
<th>Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Breast</td>
<td>64.3%</td>
<td>27.0%</td>
</tr>
<tr>
<td>Prostate</td>
<td>62.8%</td>
<td>4.7%</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>23.9%</td>
<td>46.8%</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>35.8%</td>
<td>22.2%</td>
</tr>
<tr>
<td>Melanoma</td>
<td>71.6%</td>
<td>6.6%</td>
</tr>
</tbody>
</table>

### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

- **Local**: 64.3%
- **Regional**: 27.0%
- **Distant**: 6.4%
- **Unstaged**: 22%

**Prepared by the Maryland Cancer Registry (MCR). The MCR is the state’s official source for cancer statistics. The MCR collects all new cases of reportable cancer diagnosed and/or treated in Maryland.**

**Suppressed rates:**
- Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
- Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy

**Other = Asian or Pacific Islander, American Indian, Alaskan Native**

**Percentages for cancer staging may not total 100% due to rounding**
According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Calvert County were:

Incidence: 445 new cases of all cancer cases
Mortality: 141 deaths from cancer

### Top 5 Incidence and Morality Cancer Rates, 2011-2015

<table>
<thead>
<tr>
<th>Race</th>
<th>Incidence</th>
<th>Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melanoma</td>
<td>146.9</td>
<td>45.5</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>112.6</td>
<td>28.4</td>
</tr>
<tr>
<td>Female Breast</td>
<td>59.7</td>
<td>24.9</td>
</tr>
<tr>
<td>Prostate</td>
<td>36.7</td>
<td>14.3</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>31.4</td>
<td>10.9</td>
</tr>
</tbody>
</table>

### Incidence and Mortality Rates by Race and Gender, 2011-2015

<table>
<thead>
<tr>
<th>Race</th>
<th>Incidence</th>
<th>Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male White</td>
<td>486.0</td>
<td>190.5</td>
</tr>
<tr>
<td>Female White</td>
<td>454.4</td>
<td>146.5</td>
</tr>
<tr>
<td>Male Black</td>
<td>580.5</td>
<td>260.5</td>
</tr>
<tr>
<td>Female Black</td>
<td>367.7</td>
<td>130.1</td>
</tr>
<tr>
<td>Other Male</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Other Female</td>
<td>*</td>
<td>*</td>
</tr>
</tbody>
</table>

### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

<table>
<thead>
<tr>
<th>Race</th>
<th>Local</th>
<th>Regional</th>
<th>Distant</th>
<th>Unstaged</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Breast</td>
<td>66.6%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td>67.7%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>19.9%</td>
<td>17.5%</td>
<td></td>
<td>53.8%</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>33.5%</td>
<td></td>
<td></td>
<td>19.6%</td>
</tr>
<tr>
<td>Melanoma</td>
<td>43.2%</td>
<td></td>
<td></td>
<td>54.3%</td>
</tr>
</tbody>
</table>

Prepared by the Maryland Cancer Registry (MCR). The MCR is the state’s official source for cancer statistics. The MCR collects all new cases of reportable cancer diagnosed/and or treated in Maryland.

* Suppressed rates:
  - Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
  - Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy
* Other = Asian or Pacific Islander, American Indian, Alaskan Native
**Percentages for cancer staging may not total 100% due to rounding
2015 MARYLAND INCIDENCE AND MORTALITY CANCER FACT SHEET

According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Caroline County were:

**Incidence:** 172 new cases of all cancer cases

**Mortality:** 65 deaths from cancer

---

**Top 5 Incidence and Morality Cancer Rates, 2011-2015**

**Incidence**

- Female Breast: 127.2
- Prostate: 117.6
- Lung and Bronchus: 80.4
- Colon and Rectum: 45.8
- Melanoma: 23.0

**Mortality**

- Lung and Bronchus: 61.6
- Female Breast: 20.0
- Colon and Rectum: 15.9
- Liver and intrahepatic...: 10.7
- Pancreas: *n/a*

---

**Incidence and Mortality Rates by Race and Gender, 2011-2015**

**Incidence**

- Male: 534.3, Female: 580.4
- Race: White, Black, Other, Hispanic

**Mortality**

- Male: 223.6, Female: 155.3, Other: 201.1
- Race: White, Black, Other, Hispanic

---

**Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>Local</th>
<th>Regional</th>
<th>Distant</th>
<th>Unstaged</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Breast</td>
<td>58.5%</td>
<td>70.7%</td>
<td>53.4%</td>
<td>69.8%</td>
</tr>
<tr>
<td>Prostate</td>
<td>18.0%</td>
<td>21.1%</td>
<td>34.9%</td>
<td>69.8%</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>18.6%</td>
<td>21.1%</td>
<td>34.9%</td>
<td>69.8%</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>44.2%</td>
<td>47.2%</td>
<td>32.1%</td>
<td>69.8%</td>
</tr>
<tr>
<td>Melanoma</td>
<td>69.8%</td>
<td>69.8%</td>
<td>69.8%</td>
<td>69.8%</td>
</tr>
</tbody>
</table>

Prepared by the Maryland Cancer Registry (MCR). The MCR is the state’s official source for cancer statistics. The MCR collects all new cases of reportable cancer diagnosed and/or treated in Maryland.

* Suppressed rates:
  - Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
  - Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy
  - Other = Asian or Pacific Islander, American Indian, Alaskan Native

**Percentages for cancer staging may not total 100% due to rounding**

Cancer in Maryland: 2015 Incidence and Mortality Report 37
According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Carroll County were:

**Incidence:** 1,012 new cases of all cancer cases

**Mortality:** 314 deaths from cancer

### Top 5 Incidence and Morality Cancer Rates, 2011-2015

#### Incidence Rates by Race and Gender, 2011-2015

#### Mortality Rates by Race and Gender, 2011-2015

### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

Prepared by the Maryland Cancer Registry (MCR). The MCR is the state's official source for cancer statistics. The MCR collects all new cases of reportable cancer diagnosed/and or treated in Maryland.

* Suppressed rates:
  - Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
  - Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy

**Other = Asian or Pacific Islander, American Indian, Alaskan Native

**Percentages for cancer staging may not total 100% due to rounding
According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Cecil County were:
- **Incidence:** 653 new cases of all cancer cases
- **Mortality:** 214 deaths from cancer

### Top 5 Incidence and Morality Cancer Rates, 2011-2015

#### Incidence and Mortality Rates by Race and Gender, 2011-2015

### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

Prepared by the Maryland Cancer Registry (MCR). The MCR is the state’s official source for cancer statistics. The MCR collects all new cases of reportable cancer diagnosed/and or treated in Maryland.

* Suppressed rates:
  - Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
  - Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy

Other = Asian or Pacific Islander, American Indian, Alaskan Native

**Percentages for cancer staging may not total 100% due to rounding
According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Charles County were:
- **Incidence:** 723 new cases of all cancer cases
- **Mortality:** 223 deaths from cancer

### Top 5 Incidence and Morality Cancer Rates, 2011-2015

**Incidence Rates**

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Age Adjusted Rate (per 100,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate</td>
<td>188.1</td>
</tr>
<tr>
<td>Female Breast</td>
<td>124.5</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>54.3</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>37.2</td>
</tr>
<tr>
<td>Melanoma</td>
<td>20.0</td>
</tr>
</tbody>
</table>

**Mortality Rates**

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Age Adjusted Rate (per 100,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung and Bronchus</td>
<td>40.8</td>
</tr>
<tr>
<td>Female Breast</td>
<td>24.6</td>
</tr>
<tr>
<td>Prostate</td>
<td>21.5</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>17.9</td>
</tr>
<tr>
<td>Pancreas</td>
<td>14.0</td>
</tr>
</tbody>
</table>

### Incidence and Mortality Rates by Race and Gender, 2011-2015

**Incidence Rates**

- **Male**
  - White: 518.0
  - Black: 494.9
  - Other: 240.4
- **Female**
  - White: 409.0
  - Black: 353.3
  - Other: 210.6

**Mortality Rates**

- **Male**
  - White: 198.9
  - Black: 228.8
  - Other: *
- **Female**
  - White: 153.3
  - Black: 153.1
  - Other: 126.7

### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Local</th>
<th>Regional</th>
<th>Distant</th>
<th>Unstaged</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate</td>
<td>67.3%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female Breast</td>
<td>58.8%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>21.6%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>24.9%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melanoma</td>
<td>6.1%</td>
<td>2.7%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Prepared by the Maryland Cancer Registry (MCR). The MCR is the state's official source for cancer statistics. The MCR collects all new cases of reportable cancer diagnosed/and or treated in Maryland.

* Suppressed rates:
  - **Incidence Rates** based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
  - **Mortality Rates** based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy

Other = Asian or Pacific Islander, American Indian, Alaskan Native

**Percentages for cancer staging may not total 100% due to rounding**
According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Dorchester County were:
- **Incidence:** 214 new cases of all cancer cases
- **Mortality:** 91 deaths from cancer

### Top 5 Incidence and Mortality Cancer Rates, 2011-2015

#### Incidence and Mortality Rates by Race and Gender, 2011-2015

#### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

*Suppressed rates:
* Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
* Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy

Other = Asian or Pacific Islander, American Indian, Alaskan Native

**Percentages for cancer staging may not total 100% due to rounding
2015 MARYLAND INCIDENCE AND MORTALITY CANCER FACT SHEET

According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Frederick County were:

**Incidence:** 1,342 new cases of all cancer cases
**Mortality:** 399 deaths from cancer

### Top 5 Incidence and Morality Cancer Rates, 2011-2015

#### INCIDENCE

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Male Rate</th>
<th>Female Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Breast</td>
<td>468.7</td>
<td>562.3</td>
</tr>
<tr>
<td>Prostate</td>
<td>218.2</td>
<td>243.3</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>471.6</td>
<td>295.8</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>289.9</td>
<td>25.4</td>
</tr>
<tr>
<td>Melanoma</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### MORTALITY

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Male Rate</th>
<th>Female Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung and Bronchus</td>
<td>35.7</td>
<td>14.8</td>
</tr>
<tr>
<td>Female Breast</td>
<td>21.9</td>
<td>10.0</td>
</tr>
<tr>
<td>Prostate</td>
<td>20.7</td>
<td>12.1</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>14.8</td>
<td>7.3</td>
</tr>
<tr>
<td>Pancreas</td>
<td>10.0</td>
<td>3.6</td>
</tr>
</tbody>
</table>

### Incidence and Mortality Rates by Race and Gender, 2011-2015

#### INCIDENCE

<table>
<thead>
<tr>
<th>Race</th>
<th>Male Rate</th>
<th>Female Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>63.4%</td>
<td>10.3%</td>
</tr>
<tr>
<td>Black</td>
<td>73.6%</td>
<td>9.8%</td>
</tr>
<tr>
<td>Other</td>
<td>21.9%</td>
<td>33.2%</td>
</tr>
<tr>
<td>Hispanic</td>
<td>48.2%</td>
<td>12.1%</td>
</tr>
</tbody>
</table>

#### MORTALITY

<table>
<thead>
<tr>
<th>Race</th>
<th>Male Rate</th>
<th>Female Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>33.2%</td>
<td>3.6%</td>
</tr>
<tr>
<td>Black</td>
<td>51.8%</td>
<td>8.7%</td>
</tr>
<tr>
<td>Other</td>
<td>20.6%</td>
<td>22.7%</td>
</tr>
<tr>
<td>Hispanic</td>
<td>12.1%</td>
<td>4.8%</td>
</tr>
</tbody>
</table>

### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Local</th>
<th>Regional</th>
<th>Distant</th>
<th>Unstaged</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Breast</td>
<td>48.1%</td>
<td>29.6%</td>
<td>4.8%</td>
<td>3.5%</td>
</tr>
<tr>
<td>Prostate</td>
<td>73.6%</td>
<td>12.1%</td>
<td>5.6%</td>
<td>8.7%</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>21.2%</td>
<td>51.8%</td>
<td>5.1%</td>
<td></td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>34.0%</td>
<td>20.6%</td>
<td>12.1%</td>
<td></td>
</tr>
<tr>
<td>Melanoma</td>
<td>63.4%</td>
<td>10.3%</td>
<td>3.6%</td>
<td></td>
</tr>
</tbody>
</table>

Prepared by the Maryland Cancer Registry (MCR). The MCR is the state’s official source for cancer statistics. The MCR collects all new cases of reportable cancer diagnosed/and or treated in Maryland.

* Suppressed rates:
  * Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
  * Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy

Other = Asian or Pacific Islander, American Indian, Alaskan Native

**Percentages for cancer staging may not total 100% due to rounding.
According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Garrett County were:

**Incidence:** 187 new cases of all cancer cases

**Mortality:** 75 deaths from cancer

### Top 5 Incidence and Morality Cancer Rates, 2011-2015

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Incidence Rate (per 100,000)</th>
<th>Mortality Rate (per 100,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Breast</td>
<td>105.0</td>
<td>38.3</td>
</tr>
<tr>
<td>Prostate</td>
<td>78.9</td>
<td>19.5</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>48.1</td>
<td>13.4</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>38.8</td>
<td>10.2</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>19.5</td>
<td>*</td>
</tr>
</tbody>
</table>

### Incidence and Mortality Rates by Race and Gender, 2011-2015

<table>
<thead>
<tr>
<th>Race</th>
<th>Incidence Male</th>
<th>Incidence Female</th>
<th>Mortality Male</th>
<th>Mortality Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>417.4</td>
<td>395.7</td>
<td>184.0</td>
<td>117.2</td>
</tr>
<tr>
<td>Black</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Local</th>
<th>Regional</th>
<th>Distant</th>
<th>Unstaged</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Breast</td>
<td>4.5%</td>
<td>74.1%</td>
<td>19.4%</td>
<td>36.6%</td>
</tr>
<tr>
<td>Prostate</td>
<td>0.4%</td>
<td>4.7%</td>
<td>4.7%</td>
<td>26.8%</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>19.4%</td>
<td>54.6%</td>
<td>32.9%</td>
<td>78.8%</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>36.6%</td>
<td>20.7%</td>
<td>9.8%</td>
<td>11.9%</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>78.8%</td>
<td>4.8%</td>
<td>4.8%</td>
<td>4.8%</td>
</tr>
</tbody>
</table>

Prepared by the Maryland Cancer Registry (MCR). The MCR is the state's official source for cancer statistics. The MCR collects all new cases of reportable cancer diagnosed/and or treated in Maryland.

* Suppressed rates:
  * Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
  * Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy

Other = Asian or Pacific Islander, American Indian, Alaskan Native

**Percentages for cancer staging may not total 100% due to rounding
According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Harford County were:

**Incidence:** 1,562 new cases of all cancer cases  
**Mortality:** 482 deaths from cancer

### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Local</th>
<th>Regional</th>
<th>Distant</th>
<th>Unstaged</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Breast</td>
<td>64.9%</td>
<td>9.2%</td>
<td>26.7%</td>
<td>6.7%</td>
</tr>
<tr>
<td>Prostate</td>
<td>63.6%</td>
<td>3.0%</td>
<td>24.2%</td>
<td>17%</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>22.6%</td>
<td>40.4%</td>
<td>24.4%</td>
<td>4.3%</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>32.6%</td>
<td>24.4%</td>
<td>7.7%</td>
<td>19.5%</td>
</tr>
<tr>
<td>Melanoma</td>
<td>70.4%</td>
<td>7.5%</td>
<td>2.7%</td>
<td>19.5%</td>
</tr>
</tbody>
</table>

* Percentages for cancer staging may not total 100% due to rounding

* Suppressed rates:
- Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
- Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy
Howard County

2015 MARYLAND INCIDENCE AND MORTALITY CANCER FACT SHEET

According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Howard County were:

**Incidence:** 1,339 new cases of all cancer cases

**Mortality:** 400 deaths from cancer

### Top 5 Incidence and Mortality Cancer Rates, 2011-2015

#### INCIDENCE

- Female Breast: 131.3
- Prostate: 105.2
- Lung and Bronchus: 42.8
- Colon and Rectum: 32.7
- Melanoma: 24.7

#### MORTALITY

- Lung and Bronchus: 28.4
- Female Breast: 18.8
- Prostate: 17.0
- Colon and Rectum: 10.3
- Pancreas: 9.6

### Incidence and Mortality Rates by Race and Gender, 2011-2015

#### INCIDENCE

- **Female:**
  - Male:
  - Female:

#### MORTALITY

- **Female:**
  - Male:

### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015*

- **Female Breast:**
  - Local: 69.3%
  - Regional: 47.6%
  - Distant: 12.0%
  - Unstaged: 9.2%

- **Prostate:**
  - Local: 57.4%
  - Regional: 12.9%
  - Distant: 4.2%
  - Unstaged: 25.5%

- **Lung and Bronchus:**
  - Local: 22.1%
  - Regional: 27.0%
  - Distant: 45.3%
  - Unstaged: 5.6%

- **Colon and Rectum:**
  - Local: 36.2%
  - Regional: 32.2%
  - Distant: 20.7%
  - Unstaged: 10.9%

- **Melanoma:**
  - Local: 73.0%
  - Regional: 4.5%
  - Distant: 2.5%
  - Unstaged: 20.0%

Prepared by the Maryland Cancer Registry (MCR). The MCR is the state’s official source for cancer statistics. The MCR collects all new cases of reportable cancer diagnosed/and or treated in Maryland.

* Suppressed rates:
  - Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
  - Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy

Other = Asian or Pacific Islander, American Indian, Alaskan Native

**Percentages for cancer staging may not total 100% due to rounding
According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Kent County were:
- **Incidence:** 157 new cases of all cancer cases
- **Mortality:** 49 deaths from cancer

### Top 5 Incidence and Morality Cancer Rates, 2011-2015

#### Incidence

- **Female Breast:** 146.1
- **Prostate:** 136.0
- **Lung and Bronchus:** 50.8
- **Colon and Rectum:** 35.9
- **Urinary Bladder:** 29.6

#### Mortality

- **Female Breast:** 38.2
- **Lung and Bronchus:** 27.0
- **Colon and Rectum:** 13.8
- **Pancreas:**
- **Prostate:**

### Incidence and Mortality Rates by Race and Gender, 2011-2015

#### Race

- **White:**
- **Black:**
- **Other:**
- **Hispanic:**

#### Gender

- **Male:**
- **Female:**

### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

- **Female Breast:**
- **Prostate:**
- **Lung and Bronchus:**
- **Colon and Rectum:**
- **Urinary Bladder:**

Prepared by the Maryland Cancer Registry (MCR). The MCR is the state’s official source for cancer statistics. The MCR collects all new cases of reportable cancer diagnosed/and or treated in Maryland.

* Suppressed rates:
  - Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
  - Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy

Other = Asian or Pacific Islander, American Indian, Alaskan Native

**Percentages for cancer staging may not total 100% due to rounding
According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Montgomery County were:

**Incidence:** 4,415 new cases of all cancer cases  
**Mortality:** 1,450 deaths from cancer

### Top 5 Incidence and Morality Cancer Rates, 2011-2015

#### Incidence

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Incidence Rate (per 100,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Breast</td>
<td>129.8</td>
</tr>
<tr>
<td>Prostate</td>
<td>107.7</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>31.9</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>28.9</td>
</tr>
<tr>
<td>Thyroid</td>
<td>19.5</td>
</tr>
</tbody>
</table>

#### Mortality

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Mortality Rate (per 100,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung and Bronchus</td>
<td>23.8</td>
</tr>
<tr>
<td>Female Breast</td>
<td>18.1</td>
</tr>
<tr>
<td>Prostate</td>
<td>15.7</td>
</tr>
<tr>
<td>Pancreas</td>
<td>9.3</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>9.1</td>
</tr>
</tbody>
</table>

### Incidence and Mortality Rates by Race and Gender, 2011-2015

#### Race

<table>
<thead>
<tr>
<th>Race</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>135.6</td>
<td>166.6</td>
</tr>
<tr>
<td>Black</td>
<td>94.4</td>
<td>88.5</td>
</tr>
<tr>
<td>Other</td>
<td>111.4</td>
<td>117.5</td>
</tr>
<tr>
<td>Hispanic</td>
<td>74.3</td>
<td>67.8</td>
</tr>
</tbody>
</table>

#### Gender

<table>
<thead>
<tr>
<th>Gender</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>395.4</td>
<td>453.8</td>
</tr>
<tr>
<td>Black</td>
<td>259.0</td>
<td>286.5</td>
</tr>
<tr>
<td>Other</td>
<td>286.5</td>
<td>321.7</td>
</tr>
<tr>
<td>Hispanic</td>
<td>358.3</td>
<td>371.7</td>
</tr>
</tbody>
</table>

### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Local</th>
<th>Regional</th>
<th>Distant</th>
<th>Unstaged</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Breast</td>
<td>54.3%</td>
<td>28.2%</td>
<td>4.5%</td>
<td>13.0%</td>
</tr>
<tr>
<td>Prostate</td>
<td>61.2%</td>
<td>9.0%</td>
<td>3.4%</td>
<td>25.4%</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>22.3%</td>
<td>47.8%</td>
<td>11.6%</td>
<td>12.7%</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>39.5%</td>
<td>30.5%</td>
<td>17.2%</td>
<td>12.7%</td>
</tr>
<tr>
<td>Thyroid</td>
<td>66.1%</td>
<td>28.3%</td>
<td>2.7%</td>
<td>2.7%</td>
</tr>
</tbody>
</table>
According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Prince George's County were:

**Incidence:** 3,850 new cases of all cancer cases  
**Mortality:** 1,323 deaths from cancer

## Top 5 Incidence and Morality Cancer Rates, 2011-2015

### Incidence Rates

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Age Adjusted Rate (per 100,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uterus</td>
<td>28.4</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>43.8</td>
</tr>
<tr>
<td>Female Breast</td>
<td>124.0</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>70.2</td>
</tr>
<tr>
<td>Prostate</td>
<td>143.4</td>
</tr>
</tbody>
</table>

### Morality Rates

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Age Adjusted Rate (per 100,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uterus</td>
<td>12.5</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>240.7</td>
</tr>
<tr>
<td>Female Breast</td>
<td>361.5</td>
</tr>
<tr>
<td>Prostate</td>
<td>352.5</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>377.4</td>
</tr>
</tbody>
</table>

### Incidence and Mortality Rates by Race and Gender, 2011-2015

#### Incidence

<table>
<thead>
<tr>
<th>Race</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>452.5</td>
<td>377.4</td>
</tr>
<tr>
<td>Black</td>
<td>420.1</td>
<td>361.5</td>
</tr>
<tr>
<td>Other</td>
<td>235.7</td>
<td>240.1</td>
</tr>
<tr>
<td>Hispanic</td>
<td>241.0</td>
<td>240.7</td>
</tr>
</tbody>
</table>

#### Mortality

<table>
<thead>
<tr>
<th>Race</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>199.2</td>
<td>155.4</td>
</tr>
<tr>
<td>Black</td>
<td>200.1</td>
<td>143.2</td>
</tr>
<tr>
<td>Other</td>
<td>96.8</td>
<td>74.4</td>
</tr>
<tr>
<td>Hispanic</td>
<td>93.1</td>
<td>88.8</td>
</tr>
</tbody>
</table>

## Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Local</th>
<th>Regional</th>
<th>Distant</th>
<th>Unstaged</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate</td>
<td>9.3%</td>
<td>4.2%</td>
<td>16.3%</td>
<td></td>
</tr>
<tr>
<td>Female Breast</td>
<td>31.1%</td>
<td>6.3%</td>
<td>16.4%</td>
<td></td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>44.5%</td>
<td></td>
<td>16.3%</td>
<td></td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>20.2%</td>
<td></td>
<td>17.0%</td>
<td></td>
</tr>
<tr>
<td>Uterus</td>
<td>23.8%</td>
<td></td>
<td>11.4%</td>
<td>10.7%</td>
</tr>
</tbody>
</table>

Prepared by the Maryland Cancer Registry (MCR). The MCR is the state's official source for cancer statistics. The MCR collects all new cases of reportable cancer diagnosed/and or treated in Maryland.

* Suppressed rates:
  - Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
  - Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy

Other = Asian or Pacific Islander, American Indian, Alaskan Native

**Percentages for cancer staging may not total 100% due to rounding
According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Queen Anne's County were:

**Incidence:** 292 new cases of all cancer cases

**Mortality:** 91 deaths from cancer

### Top 5 Incidence and Morality Cancer Rates, 2011-2015

#### Incidence

- **Female Breast:** 113.7 per 100,000
- **Prostate:** 102.2 per 100,000
- **Lung and Bronchus:** 62.2 per 100,000
- **Melanoma:** 30.9 per 100,000
- **Colon and Rectum:** 29.4 per 100,000

#### Mortality

- **Lung and Bronchus:** 49.0 per 100,000
- **Prostate:** 24.5 per 100,000
- **Female Breast:** 18.9 per 100,000
- **Pancreas:** 11.6 per 100,000
- **Colon and Rectum:** 10.0 per 100,000

### Incidence and Mortality Rates by Race and Gender, 2011-2015

#### Incidence

<table>
<thead>
<tr>
<th>Race</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>480.6</td>
<td>409.0</td>
</tr>
<tr>
<td>Black</td>
<td>532.1</td>
<td>368.9</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Mortality

<table>
<thead>
<tr>
<th>Race</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>212.5</td>
<td>130.9</td>
</tr>
<tr>
<td>Black</td>
<td>250.3</td>
<td>171.3</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

- **Female Breast:**
  - Local: 63.8%
  - Regional: 72.9%
  - Distant: 26.7%
  - Unstaged: 4.9%

- **Prostate:**
  - Local: 28.6%
  - Regional: 45.1%
  - Distant: 4.9%
  - Unstaged: 8.2%

- **Lung and Bronchus:**
  - Local: 38.2%
  - Regional: 59.3%
  - Distant: 4.9%
  - Unstaged: 5.6%

- **Melanoma:**
  - Local: 38.2%
  - Regional: 59.3%
  - Distant: 4.9%
  - Unstaged: 5.6%

- **Colon and Rectum:**
  - Local: 38.2%
  - Regional: 59.3%
  - Distant: 4.9%
  - Unstaged: 5.6%

Prepared by the Maryland Cancer Registry (MCR). The MCR is the state’s official source for cancer statistics. The MCR collects all new cases of reportable cancer diagnosed/and or treated in Maryland.

* Suppressed rates:
  - Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
  - Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy

Other = Asian or Pacific Islander, American Indian, Alaskan Native

**Percentages for cancer staging may not total 100% due to rounding
According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Somerset County were:
- **Incidence:** 148 new cases of all cancer cases
- **Mortality:** 52 deaths from cancer

### Top 5 Incidence and Morality Cancer Rates, 2011-2015

**Incidence:**
- Female Breast: 111.1
- Prostate: 110.3
- Lung and Bronchus: 88.8
- Colon and Rectum: 48.2
- Urinary Bladder: 23.5

**Mortality:**
- Lung and Bronchus: 74.0
- Colon and Rectum: 46.4
- Liver & Intrahepatic Bile: 42.7
- Pancreas: 11.1

### Incidence and Mortality Rates by Race and Gender, 2011-2015

**Incidence by Race and Gender:**
- **Male:**
  - White: 546.1
  - Black: 515.7
  - Other: ...

- **Female:**
  - White: 454.1
  - Black: 427.4
  - Other: ...

**Mortality by Race and Gender:**
- **Male:**
  - White: 236.0
  - Black: 259.4
  - Other: ...

- **Female:**
  - White: 167.3
  - Black: 177.1
  - Other: ...

### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

**Female Breast:**
- Local: 64.6%
- Regional: 22.5%
- Distant: 5.4%
- Unstaged: 5.5%

**Prostate:**
- Local: 77.8%
- Regional: 12.7%
- Distant: 3.0%
- Unstaged: 5.4%

**Lung and Bronchus:**
- Local: 17.4%
- Regional: 29.7%
- Distant: 46.4%
- Unstaged: 6.5%

**Colon and Rectum:**
- Local: 37.0%
- Regional: 30.1%
- Distant: 26.0%
- Unstaged: 6.8%

**Urinary Bladder:**
- Local: 83.1%
- Regional: 5.4%
- Distant: 8.1%
- Unstaged: 5.4%

Prepared by the Maryland Cancer Registry (MCR). The MCR is the state's official source for cancer statistics. The MCR collects all new cases of reportable cancer diagnosed/and or treated in Maryland.

* Suppressed rates:
  - Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
  - Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy

Other = Asian or Pacific Islander, American Indian, Alaskan Native

**Percentages for cancer staging may not total 100% due to rounding**
According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in St. Mary's County were:
- **Incidence:** 517 new cases of all cancer cases
- **Mortality:** 194 deaths from cancer

### Top 5 Incidence and Morality Cancer Rates, 2011-2015

**Incidence**
- Female Breast: 109.3
- Prostate: 83.5
- Lung and Bronchus: 65.9
- Colon and Rectum: 32.6
- Melanoma: 30.2

**Mortality**
- Lung and Bronchus: 52.3
- Female Breast: 23.0
- Colon and Rectum: 13.3
- Pancreas: 11.0
- Liver and Intrahepatic: 8.6

### Incidence and Mortality Rates by Race and Gender, 2011-2015

**Incidence**
- **Male:**
  - White: 445.6
  - Black: 464.2
  - Hispanic: 260.2
  - Other: 418.1
- **Female:**
  - White: 341.9
  - Black: 228.4
  - Hispanic: 293.3

**Mortality**
- **Male:**
  - White: 223.5
  - Black: 155.8
  - Hispanic: * *
  - Other: 127.2
- **Female:**
  - White: 226.1
  - Black: * *
  - Hispanic: * *

### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Local</th>
<th>Regional</th>
<th>Distant</th>
<th>Unstaged</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Breast</td>
<td>63.6%</td>
<td>5.4%</td>
<td>2.5%</td>
<td>28.5%</td>
</tr>
<tr>
<td>Prostate</td>
<td>58.1%</td>
<td>12.6%</td>
<td>2.3%</td>
<td>26.8%</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>23.4%</td>
<td>27.7%</td>
<td>37.8%</td>
<td>12.0%</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>32.1%</td>
<td>39.1%</td>
<td>20.1%</td>
<td>8.7%</td>
</tr>
<tr>
<td>Melanoma</td>
<td>48.8%</td>
<td>8.4%</td>
<td>2.4%</td>
<td>40.4%</td>
</tr>
</tbody>
</table>

Prepared by the Maryland Cancer Registry (MCR). The MCR is the state's official source for cancer statistics. The MCR collects all new cases of reportable cancer diagnosed/and or treated in Maryland.

* Suppressed rates:
  - Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
  - Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy

Other = Asian or Pacific Islander, American Indian, Alaskan Native

**Percentages for cancer staging may not total 100% due to rounding
According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Talbot County were:

**Incidence:** 292 new cases of all cancer cases

**Mortality:** 85 deaths from cancer

### Top 5 Incidence and Mortality Cancer Rates, 2011-2015

<table>
<thead>
<tr>
<th>Incidence</th>
<th>Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Breast</td>
<td>Lung and Bronchus</td>
</tr>
<tr>
<td>Prostate</td>
<td>Prostate</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>Female Breast</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>Pancreas</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>Colon and Rectum</td>
</tr>
</tbody>
</table>

**Prepared by the Maryland Cancer Registry (MCR). The MCR is the state’s official source for cancer statistics. The MCR collects all new cases of reportable cancer diagnosed/and or treated in Maryland.**

* Suppressed rates:
  - Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
  - Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy

**other** = Asian or Pacific Islander, American Indian, Alaskan Native

**Percentages for cancer staging may not total 100% due to rounding**
According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Washington County were:

**Incidence:** 822 new cases of all cancer cases

**Mortality:** 297 deaths from cancer

### Top 5 Incidence and Morality Cancer Rates, 2011-2015

#### INCIDENCE

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Incidence Rate (per 100,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Breast</td>
<td>135.0</td>
</tr>
<tr>
<td>Prostate</td>
<td>94.1</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>66.8</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>37.3</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>23.3</td>
</tr>
</tbody>
</table>

#### MORTALITY

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Mortality Rate (per 100,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung and Bronchus</td>
<td>48.8</td>
</tr>
<tr>
<td>Female Breast</td>
<td>23.5</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>17.2</td>
</tr>
<tr>
<td>Prostate</td>
<td>17.0</td>
</tr>
<tr>
<td>Pancreas</td>
<td>10.4</td>
</tr>
</tbody>
</table>

### Incidence and Mortality Rates by Race and Gender, 2011-2015

#### INCIDENCE

- **Male**
  - White: 479.8
  - Black: 534.5
  - Other: 370.3
  - Hispanic: 450.1

- **Female**
  - White: 465.3
  - Black: 369.8
  - Other: 278.7
  - Hispanic: 486.8

#### MORTALITY

- **Male**
  - White: 205.5
  - Black: 177.6
  - Other: *
  - Hispanic: *

- **Female**
  - White: 154.1
  - Black: 124.7
  - Other: *
  - Hispanic: *

### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Local</th>
<th>Regional</th>
<th>Distant</th>
<th>Unstaged</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Breast</td>
<td>68.5%</td>
<td>18.1%</td>
<td>6.1%</td>
<td>6.1%</td>
</tr>
<tr>
<td>Prostate</td>
<td>72.2%</td>
<td>17.9%</td>
<td>4.5%</td>
<td>4.5%</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>18.6%</td>
<td>28.0%</td>
<td>49.7%</td>
<td>4.3%</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>36.9%</td>
<td>33.9%</td>
<td>24.1%</td>
<td>5.1%</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>86.4%</td>
<td>3.2%</td>
<td>5.0%</td>
<td>5.5%</td>
</tr>
</tbody>
</table>

**Prepared by the Maryland Cancer Registry (MCR). The MCR is the state’s official source for cancer statistics. The MCR collects all new cases of reportable cancer diagnosed/and or treated in Maryland.

* Suppressed rates:
  - Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
  - Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy

Other = Asian or Pacific Islander, American Indian, Alaskan Native

**Percentages for cancer staging may not total 100% due to rounding**
According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Wicomico County were:

**Incidence:** 635 new cases of all cancer cases

**Mortality:** 220 deaths from cancer

---

### Top 5 Incidence and Morality Cancer Rates, 2011-2015

#### Incidence and Mortality Rates by Race and Gender, 2011-2015

#### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

Prepared by the Maryland Cancer Registry (MCR). The MCR is the state's official source for cancer statistics. The MCR collects all new cases of reportable cancer diagnosed/and or treated in Maryland.

* Suppressed rates:
  - Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures
  - Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy

Other = Asian or Pacific Islander, American Indian, Alaskan Native

**Percentages for cancer staging may not total 100% due to rounding

Cancer in Maryland: 2015 Incidence and Mortality Report

54
According to the Maryland Cancer Registry, a total of 31,001 Maryland residents were diagnosed with cancer in 2015. Cancer remains the second leading cause of death among people in Maryland, exceeded only by heart disease.

In 2015, the number of incidence and mortality cases in Worcester County were:

**Incidence:** 453 new cases of all cancer cases  
**Mortality:** 174 deaths from cancer

### Top 5 Incidence and Morality Cancer Rates, 2011-2015

#### Incidence

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>Age Adjusted Rate (per 100,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Breast</td>
<td>135.7</td>
</tr>
<tr>
<td>Prostate</td>
<td>114.9</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>66.9</td>
</tr>
<tr>
<td>Melanoma</td>
<td>43.4</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>39.6</td>
</tr>
</tbody>
</table>

#### Mortality

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>Age Adjusted Rate (per 100,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung and Bronchus</td>
<td>54.2</td>
</tr>
<tr>
<td>Female Breast</td>
<td>27.9</td>
</tr>
<tr>
<td>Prostate</td>
<td>22.9</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>13.3</td>
</tr>
<tr>
<td>Pancreas</td>
<td>9.7</td>
</tr>
</tbody>
</table>

### Incidence and Mortality Rates by Race and Gender, 2011-2015

#### Incidence

<table>
<thead>
<tr>
<th>Race</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>526.3</td>
<td>445.1</td>
</tr>
<tr>
<td>Black</td>
<td>663.2</td>
<td>455.2</td>
</tr>
<tr>
<td>Other</td>
<td>*</td>
<td>*</td>
</tr>
</tbody>
</table>

#### Mortality

<table>
<thead>
<tr>
<th>Race</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>209.1</td>
<td>148.6</td>
</tr>
<tr>
<td>Black</td>
<td>366.0</td>
<td>149.5</td>
</tr>
<tr>
<td>Other</td>
<td>*</td>
<td>*</td>
</tr>
</tbody>
</table>

### Distribution of Cancer Stage at Diagnosis, Top 5 Incidence Cancer Rates, 2011-2015**

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>Local</th>
<th>Regional</th>
<th>Distant</th>
<th>Unstaged</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Breast</td>
<td>62.6%</td>
<td>10.3%</td>
<td>4.8%</td>
<td>19.3%</td>
</tr>
<tr>
<td>Prostate</td>
<td>77.1%</td>
<td>10.3%</td>
<td>6.9%</td>
<td>5.7%</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>18.8%</td>
<td>22.4%</td>
<td>50.0%</td>
<td>8.8%</td>
</tr>
<tr>
<td>Melanoma</td>
<td>37.7%</td>
<td>30.2%</td>
<td>22.8%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>30.2%</td>
<td>30.2%</td>
<td>22.8%</td>
<td>30.7%</td>
</tr>
</tbody>
</table>

* Suppressed rates:  
  - Incidence Rates based on case counts of 1-15 are suppressed per MDH / MCR Data Use Policy and Procedures  
  - Mortality Rates based on death counts of 0-19 are suppressed per MDH / CCPC Mortality Data Suppression Policy  
* Other = Asian or Pacific Islander, American Indian, Alaskan Native  
**Percentages for cancer staging may not total 100% due to rounding
APPENDIX A

2000 U.S. STANDARD POPULATION
This page left blank intentionally
## 2000 U.S. STANDARD POPULATION

(CENSUS P25-1130)

<table>
<thead>
<tr>
<th>Age Group</th>
<th>2000 Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than 00 age</td>
<td>3,794,901</td>
</tr>
<tr>
<td>01-04 years</td>
<td>15,191,619</td>
</tr>
<tr>
<td>05-09 years</td>
<td>19,919,840</td>
</tr>
<tr>
<td>10-14 years</td>
<td>20,056,779</td>
</tr>
<tr>
<td>15-19 years</td>
<td>19,819,518</td>
</tr>
<tr>
<td>20-24 years</td>
<td>18,257,225</td>
</tr>
<tr>
<td>25-29 years</td>
<td>17,722,067</td>
</tr>
<tr>
<td>30-34 years</td>
<td>19,511,370</td>
</tr>
<tr>
<td>35-39 years</td>
<td>22,179,956</td>
</tr>
<tr>
<td>40-44 years</td>
<td>22,479,229</td>
</tr>
<tr>
<td>45-49 years</td>
<td>19,805,793</td>
</tr>
<tr>
<td>50-54 years</td>
<td>17,224,359</td>
</tr>
<tr>
<td>55-59 years</td>
<td>13,307,234</td>
</tr>
<tr>
<td>60-64 years</td>
<td>10,654,272</td>
</tr>
<tr>
<td>65-69 years</td>
<td>9,409,940</td>
</tr>
<tr>
<td>70-74 years</td>
<td>8,725,574</td>
</tr>
<tr>
<td>75-79 years</td>
<td>7,414,559</td>
</tr>
<tr>
<td>80-84 years</td>
<td>4,900,234</td>
</tr>
<tr>
<td>85+ years</td>
<td>44,259,17</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>274,633,642</strong></td>
</tr>
</tbody>
</table>

Source: National Cancer Institute- SEER 2000
APPENDIX B

GLOSSARY
This page left blank intentionally
GLOSSARY

- **Age-adjustment**: Age is the most important risk factor for the incidence of most cancers. However, cancer rates derived from populations that differ in underlying age structure are not comparable. Age-adjustment is a statistical technique that allows for the comparison of rates among populations with different age distributions, by weighting the age-specific rates in each population to one standard population. Additional information on age-adjustment can be found on the following web sites:


- **Ascertainment**: Refers to the quality assurance procedures that Maryland Cancer Registry staff use to ensure completeness of cancer cases in the Registry database. These activities include: a review of disease indices from all reporting hospitals to identify possible missed cases; an evaluation of random samples of records from reporting facilities; and a review of death certificate data to identify cancer cases not previously reported.

- **Cancer**: A disease characterized by the uncontrolled, abnormal growth of cells in different parts of the body that can spread to other parts of the body.

- **Confidence interval (CI)**: The range of values for a calculated estimate that will include the true value a given percentage of the time. A 95% CI for a rate includes the true rate 95% of the time.

- **Incidence**: The number of new cases of a given cancer or other event during a defined time period, usually one year. For the purposes of this report, cancer incidence refers to the number of new cases diagnosed during the individual calendar year 2012. Cancer incidence data are also presented in aggregated form, as the average annual incidence for the 5-year period from 2008 through 2012.

- **International Classification of Diseases (ICD)**: The ICD is the international standard diagnostic classification for all general epidemiological, health management, and clinical use. It is used to classify diseases and other health problems recorded on many types of health and vital records, including death certificates and health records.

- **International Classification of Diseases for Oncology (ICD-O)**: The ICD-O is the classification system used by tumor or cancer registries to code the site and the histology of the cancer, usually from a pathology report.
• **Invasive cancer:** Cancer that has spread beyond the layer of cells where it first began and has grown into nearby tissues. It may still be considered local stage if it has not spread to other parts of the body. Stage data presented in this report involve a diagnosis of invasive cancer: local, regional, or distant. A diagnosis of *in situ* is non-invasive and is not included in the staging data, except for *in situ* bladder cancer for all sites cancer data.

• **Mortality:** The number of deaths during a defined time period, usually one year. For the purposes of this report, cancer mortality refers to the number of new cancer deaths during the individual calendar year 2012. Cancer mortality data are also presented in an aggregated form, as the average annual mortality for the 5-year period from 2008 through 2012.

• **Rate:** An estimate of the burden of a given disease on a defined population at risk over a specified period of time. A crude rate is calculated by dividing the number of cases or deaths (events) by the population at risk during a given time period. Cancer incidence and mortality rates are usually presented per 100,000 population during a given time period. An incidence rate is the number of new cases during a specific period (usually one year) divided by the population at risk per 100,000 population. A mortality rate is the number of deaths for a given period divided by the population at risk per 100,000 population. All rates presented in this report are age-adjusted to the 2000 U.S. standard population.

• **Stage at diagnosis:** Cancer stage is the extent to which the cancer has spread from the organ of origin at the time of diagnosis. The stage information used in this report is based on the SEER Summary Stage Guidelines:

1. **In situ:** The cancerous cells have not invaded the tissue basement membrane and no stromal invasion. *In situ* cancers are not considered malignant (with the exception of bladder cancers) and are not included in incidence rate calculations.
2. **Local:** The tumor is confined to the organ of origin.
3. **Regional:** The tumor has spread to adjacent organs or tissue. Regional lymph nodes may also be involved.
4. **Distant:** The tumor has spread beyond the adjacent organs or tissues. Distant lymph nodes, organs, and/or tissues may also be involved.
5. **Unstaged:** The stage of disease at diagnosis could not be classified (often due to insufficient information) or was not reported to the cancer registry.
For comments or questions about this report, contact:
Maryland Cancer Registry
Center for Cancer Prevention and Control
Maryland Department of Health
201 W. Preston Street
Baltimore, Maryland 21201
Telephone: 410-767-4055
Fax: 410-333-5218
The services and facilities of the Maryland Department of Health (MDH) are operated on a non-discriminatory basis. This policy prohibits discrimination on the basis of race, color, sex, or national origin and applies to the provisions of employment and granting of advantages, privileges and accommodations.

The Department, in compliance with the Americans with Disabilities Act, ensures that qualified individuals with disabilities are given an opportunity to participate in and benefit from MDH services, programs, benefits, and employment opportunities.